      
 
Clinical  Investigation  Plan for  
QP ExCELs  U.S. 
 
 
 
 
Sentus QP – Extended CRT Evaluation with 
Quadripolar  Left Ventricular Leads 
EP PASSION/MPP Sub -Study Amendment  
[STUDY_ID_REMOVED]  
 
 
September 6 , 2019 
 
 
 
BIOTRONIK, Inc.  
6024 Jean Road, Lake Oswego, OR 97035  
 
This documen t contains confidential information for use only by investigators  and 
clinical sites  participating in the  clinical study . Therefore, this document should be 
maintained in a secure location and should not be copied or made available for 
review by any unauth orized personnel.  
    QP ExCELs  
 
Version: September 6 , 2019   Page 1 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Table of Contents  
1. INTRODUCTION  ................................ ................................ ................................ ........................  7 
1.1 Study Overview  ................................ ................................ ................................ ..................  7 
1.2 Background  ................................ ................................ ................................ ........................  7 
1.2.1  Published Results for Multipoint LV Pacing ................................ ............................  8 
1.3 Devices  ................................ ................................ ................................ ..............................  9 
1.3.1  Sentus QP Lead  ................................ ................................ ................................ ..... 9 
1.3.2  Pacing and Sensing Vector Options  ................................ ................................ ..... 10 
1.3.3  MultiPole  Pacing (MPP) Description  ................................ ................................ .... 12 
2. STUDY DESIGN  ................................ ................................ ................................ ......................  16 
2.1 Objectives  ................................ ................................ ................................ ........................  17 
2.1.1 Primary Endpoint 1  ................................ ................................ ...............................  17 
2.1.2  Secondary Endpoint 1  ................................ ................................ ..........................  18 
2.1.3  Secondary Endpoint 2  ................................ ................................ ..........................  18 
2.1.4  Secondary Endpoint 3  ................................ ................................ ..........................  18 
2.1.5  Additional Data of Interest  ................................ ................................ ....................  19 
2.2 Subject Status Definitions  ................................ ................................ ................................  19 
2.3 Study Size and Duration  ................................ ................................ ................................ .. 20 
2.3.1  MPP Sub -Study Sample Size Analysis  ................................ ................................  21 
2.3.1.1  Primary Endpoint 1 Sample Size  ................................ ................................ ................  21 
2.4 Interim Analysis  ................................ ................................ ................................ ................  22 
2.5 Adjustments to Overall Sample Size  ................................ ................................ ...............  22 
2.6 Data Analyses  ................................ ................................ ................................ ..................  22 
2.6.1  Replacement of Missing Data  ................................ ................................ ..............  23 
2.6.2  MPP Sub -Study Analysis Population  ................................ ................................ ... 23 
3. PROTOCOL REQUIREMENT S ................................ ................................ ...............................  24 
3.1 Subject Population  ................................ ................................ ................................ ...........  24 
3.1.1  Indications for  Use ................................ ................................ ................................  24 
3.1.2  Contraindications  ................................ ................................ ................................ .. 24 
3.1.3  Inclusion Criteria  ................................ ................................ ................................ ... 24 
3.1.4  Exclusion Criteria  ................................ ................................ ................................ .. 25 
3.2 Methods  ................................ ................................ ................................ ...........................  26 
3.2.1  eCRFs  ................................ ................................ ................................ ...................  26 
3.2.2  Subject Demog raphics, Comorbidities and Medications  ................................ ...... 26 
3.2.3  Device Settings  ................................ ................................ ................................ ..... 27 
3.2.4  CRT Based Lead Measurements  ................................ ................................ .........  27 
3.2.5  New York Heart Association (NYHA) Classification  ................................ .............  27 
3.2.6  Patient Global Assessment (PGA)  ................................ ................................ ....... 28 
3.3 Study Procedures  ................................ ................................ ................................ ............  28 
3.3.1  Overview of Study Procedures  ................................ ................................ .............  30 
3.3.2  QP ExCELs Enrollment  ................................ ................................ ........................  31 
3.3.3  Implantation  ................................ ................................ ................................ ..........  31 
3.3.4  QP ExCELs 6 -month Follow -up ................................ ................................ ...........  32 
3.3.5  MPP Sub -Study Enrollment  ................................ ................................ ..................  33 
    QP ExCELs  
 
Version: September 6 , 2019   Page 2 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
3.3.6  3-Month MPP Follow -up ................................ ................................ .......................  34 
3.3.7  6-Month MPP Follow -up ................................ ................................ .......................  34 
3.3.8  Interim Follow -up ................................ ................................ ................................ .. 34 
3.3.8.1  MPP Sub -Study Heart Failure Hospitalization  ................................ ............................  35 
3.3.8.2  Adverse event related interim follow -up ................................ ................................ ..... 35 
3.3.8.3  System Revision  ................................ ................................ ................................ ........  35 
3.3.9  Study Termination  ................................ ................................ ................................  36 
3.4 Study Participation Expectations  ................................ ................................ .....................  36 
3.4.1  Point of Enrollment  ................................ ................................ ...............................  36 
3.4.2  Reasons for Study Termination  ................................ ................................ ............  36 
3.4.2.1  No implant attempt  ................................ ................................ ................................ ..... 36 
3.4.2.2  Withdrawal of subject consent  ................................ ................................ ....................  37 
3.4.2.3  Subject death  ................................ ................................ ................................ .............  37 
3.4.2.4  Sentus QP lead or BIOTRONIK CRT -D extraction  ................................ .....................  37 
3.4.2.5  Lost to follow -up ................................ ................................ ................................ .........  37 
3.4.2.6  MPP Sub -Study Completion  ................................ ................................ .......................  38 
3.4.3  Date of Study Termination  ................................ ................................ ....................  38 
4. ADDITIONAL STUDY CON DITIONS  ................................ ................................ ......................  39 
4.1 IRB Approval  ................................ ................................ ................................ ....................  39 
4.2 Subject Consent  ................................ ................................ ................................ ...............  39 
4.3 Data Collection  ................................ ................................ ................................ .................  39 
4.3.1  Electronic Data Capture (EDC)  ................................ ................................ ............  39 
4.3.2  Electronic Case Report Forms (eCRFs)  ................................ ...............................  39 
4.3.3  BIOTRONIK Home Monitoring® Data  ................................ ................................ ... 40 
4.4 Confidentiality of Subject Data  ................................ ................................ .........................  40 
4.5 Data Quality Control  ................................ ................................ ................................ .........  40 
4.6 Deviations from Clinical Investigation Plan  ................................ ................................ ...... 40 
4.6.1  Protocol Violations  ................................ ................................ ................................  41 
4.6.2  Protocol Deviations  ................................ ................................ ...............................  41 
4.6.3  IRB Reporting of Non -Compliance  ................................ ................................ ....... 41 
4.7 Subject Retention  ................................ ................................ ................................ .............  41 
4.8 Study Completion  ................................ ................................ ................................ .............  42 
5. STUDY OVERSIGHT  ................................ ................................ ................................ ...............  43 
5.1 Clinical Events Committee  ................................ ................................ ...............................  43 
5.1.1  Clinical Eve nts Committee – MPP Sub -Study Events  ................................ ..........  43 
6. ADVERSE EVENTS  ................................ ................................ ................................ ................  44 
6.1 Definitions  ................................ ................................ ................................ ........................  44 
6.1.1  Definition of Adverse Event  ................................ ................................ ..................  44 
6.1.2  Definition of Adverse Device Effect  ................................ ................................ ...... 44 
6.1.3  Serious AEs, ADEs  ................................ ................................ ...............................  45 
6.1.4  Definition of Heart Failure Hospitalization  ................................ ............................  45 
6.2 Reporting Adverse Events  ................................ ................................ ...............................  45 
6.3 Reportable Adverse Events  ................................ ................................ .............................  47 
6.3.1  Lead, System, and Procedure Related Event Examples  ................................ ..... 47 
6.3.2  Reporting Hospitalizations  ................................ ................................ ....................  48 
    QP ExCELs  
 
Version: September 6 , 2019   Page 3 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
6.3.3  MPP Feature Related Adverse Events  ................................ ................................ . 48 
6.4 Sponsor Reporting  ................................ ................................ ................................ ...........  49 
7. OTHER INSTITUTIONS A ND PHYSICIANS ................................ ................................ ........... 50 
8. RISKS AND BENEFITS ................................ ................................ ................................ ........... 51 
8.1.1  Potential Benefits  ................................ ................................ ................................ .. 51 
8.1.2  Potential Risks  ................................ ................................ ................................ ...... 51 
9. MONITORING  ................................ ................................ ................................ ..........................  52 
9.1 Summary  ................................ ................................ ................................ ..........................  52 
9.2 Monitors  ................................ ................................ ................................ ...........................  53 
10. RECORDS AND REPORTS  ................................ ................................ ................................ .... 54 
10.1  Investigator Records  ................................ ................................ ................................ ........  54 
10.2  Investigator Reports  ................................ ................................ ................................ .........  54 
10.3  Sponsor Records and Reports  ................................ ................................ ........................  55 
11. REFERENCES  ................................ ................................ ................................ .........................  57 
12. APPENDIX A: DEFINITI ON OF TERMS  ................................ ................................ .................  60 
13. APPENDIX B: PREVIOUS LY IDENTIFIED ADVERS E EVENTS  ................................ .......... 64 
 
    QP ExCELs  
 
Version: September 6 , 2019   Page 4 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
 
Table o f Figures  
Figure 1: Sentus QP Lead Tip Design  ................................ ................................ ...........................  10 
Figure 2: Programmer Display of LV Pacing Polarity  ................................ ................................ .... 12 
Figure 3: Programming MultiPole Pacing  ................................ ................................ ......................  13 
Figure 4: Programming 1st LV Stimulus  ................................ ................................ .........................  14 
Figure 5: Programming 2nd LV Stimulus  ................................ ................................ ........................  14 
Figure 6: V -V Delay, LV First  ................................ ................................ ................................ .........  15 
Figure 7: V-V Delay, RV First  ................................ ................................ ................................ ........  15 
Figure 8: Clinical Study Design  ................................ ................................ ................................ ..... 29 
 
Table of Tables  
Table 1: LV Pacing and Sensing Configurations  ................................ ................................ ...........  11 
Table 2: Programmable Par ameters for MultiPole Pacing  ................................ ............................  13 
Table 3: Subject Status Definitions ................................ ................................ ................................  20 
Table 4: Recommended Device Settings  ................................ ................................ ......................  27 
Table 5: Required Visit Windows for MPP Sub -Study ................................ ................................ ... 30 
Table 6: Procedures by Visit Type ................................ ................................ ................................ . 30 
Table 7: Investigator Reports  ................................ ................................ ................................ ........  55 
Table 8: Sponsor Reporting Responsibilities  ................................ ................................ ................  56 
Table 9 : Expected Perioperative Events  ................................ ................................ .......................  64 
 
 
 
    QP ExCELs  
 
Version: September 6 , 2019   Page 5 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
 
QP ExCELs  
Sentus QP – Extended CRT Evaluation with Quadripolar  
Left Ventricular Leads 
EP PASSION/MPP Sub -Study Amendment  
 
Protocol Version – September 6 , 2019 
 
PROTOCOL SIGNATURE PAGE  
The signature below documents  receipt and revi ew of the  QP ExCELs  study  
protocol and any attachments, and provides assurance that this study  will be 
conducted according to all stipulations of the protocol, including all statements 
regarding confidentiality, and according to local legal and regulatory 
requirements and applicable guidelines.  
 
 
Principal Investigator : 
 
   
Name (please print)  
 
   
Signature   Date 
 
    QP ExCELs  
 
Version: September 6 , 2019   Page 6 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Summary  
Title Sentus QP – Extended CRT Evaluation with Quadripolar 
Left Ventricular Leads 
EP PASSION/MPP Sub -Study Amendment  
Acronym  QP ExC ELs 
Subject  collective  Heart f ailure subjects  with standard CRT -D indication 
according to clinical routine.  
Design  
 
 
 Single -arm, multi -center,  and prospective trial. The MPP 
sub-study is designed to fulfill the FDA required post -
aproval study for the U S market released BIOTRONIK 
MultiPole Pacing (MPP) feature (PMA P050023/S107) of 
the Ilivia HF -T QP family CRT -D system (PMA 
P050023/S103), or Acticor/Rivacor HF -T QP family CRT -
D system (PMA P050023/S125).  
Objectives  The primary objective of this clinical  investigation is to 
convert a percentage of CRT non -reponders to 
responders using the MultiPole Pacing (MPP) feature.  
Primary Endpoint  Evaluation of the CRT responder status with the MPP 
feature  
Secondary 
Endpoints  1. Freedom from MPP system -related compl ications  
at 6 months post MPP enrollment.  
2. Clinical composite score + patient global 
assessment responder status  
3. Clinical composite score responder status utilizing 
a modified responder classification  
Sample Size  QP ExCELs study: up to 1,754 subjects enrol led in U.S . 
MPP sub -study: up to  110 subjects within the U.S. who 
are participating in the QP ExCELs study.  
Investigational Sites  Up to 75 sites within the United States  
Follow -up period  All subjects will be followed up to 6 months for screening 
into the  MPP sub -study. If the MPP inclusion/exclusion 
criteria  are met at screening , the subject will be followed 
an additional 6 months.   
Sponsor  BIOTRONIK, Inc.  
Clinical Studies Department  
6024 Jean Road  
Lake Oswego, Oregon 97035  
 
    QP ExCELs  
 
Version: September 6 , 2019   Page 7 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
1. INTRODUCTION  
1.1 Study Overview  
The QP ExCELs study protocol was designed to support  a pre -market study 
phase and an FDA required post -approval registry phase for BIOTRONIK’s 
Sentus QP lead.  In addition, the QP ExCELs protocol  supports  an FDA required 
post-approval MultiPole Pacing (MPP ) sub -study to demonstrate the MPP feature 
can effectively convert a percentage of CRT non -responders to responders.   
Upon completion of the pre -market analysis and approval of the Sentus QP LV 
lead (P070008/S079, approved May 4, 2017) , enrollment into the  QP ExCELs 
study was continued to fulfill the post -approval study requirements . On 
September 24th, 2019 , BIOTRONIK received FDA approval to transition the QP 
ExCELs Study protocol to the Sentus QP EP P ASSION Post -Approval Study 
Protocol.  The purpose of thi s clinical study protocol amendment is to support the  
continuation of the MPP s ub-study while the QP ExCELs Post -Approval Study 
protocol is transitioned to the Sentus QP EP PASSION Post -Approval Study 
protocol.   
Subjects eligible for the study are receivin g or have recently received  a new ( de 
novo ) implant or undergoing an upgrade from an existing ICD or pacemaker 
implant with no prior attempt at LV lead placement. Prior to enrollment, eligible 
subjects will be identified and will provide written informed c onsent, which will 
include consent to participate in the QP ExCELs  study  and the MPP sub -study. 
Subjects will be  screened for the MPP sub -study  at the 6 month in -office follow -
up, or between 3 months and 6 months post -implant if the patient has a heart 
failure hospitalization . Those subjects satisfying the MPP sub -study inclusion  and 
exclusion criteria will continue  into the MPP sub -study  and be seen for additional 
follow -up visits at 3 months and  6 months after MPP sub -study enrollment  (See 
Section 3.3 for details). No further study visits will be completed for subjects that 
do not qualify for the MPP sub -study .  
All devices utilized in conjunction with this study are U.S.  market approved  and 
prescribed by physicians according t o approved indications for use . 
1.2 Background  
Heart failure (HF) is a major public health issue with a current prevalence of 2 -
3% in the total and 10 -20% in the aged population (Lloyd -Jones et al., 2010) . The 
overall prevalence for heart f ailure is increasing due to aging population. 
Additional factors are the success of the modern therapies  in prolongation of 
survival of patients suffering from coronary events and the effective prevention of 
death for patients being at high risk.  
The overall mortality for the populat ion is 50% in the first 4 years and  40% of the 
patients with HF -related hosp italizations have to be readmitted to hospital or die 
within one year (Dickstein et al., 2008) . 
    QP ExCELs  
 
Version: September 6 , 2019   Page 8 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Cardiac Resynchronization Therapy (CRT) is used in order to sync hronize 
interventricular and intraventricular contraction pattern of the heart i n patients 
with heart f ailure in whom there is evidence of electrical dyssynchrony (QRS 
width ≥120 ms). CRT with defibrillator function (CRT -D) is recommended to 
reduce morbidi ty and mortality in patients in NYHA class III-IV who are 
symptomatic despite optimal medical therapy and suffer from a reduced left 
ventricular ejection fraction (LVEF ≤ 35%, (Dickstein et al., 2008) ). This indication 
has been recently extended to patients in NYHA class II (Dickstein et al., 2010) . 
Despite the proven benefit of CRT in  the indicated population, up to one -third of 
patients do not respond to the therapy  (Rinaldi et al., 2015) . The combination of 
the BIOTRONIK left ventricular lead family Sentus QP  with the corresponding 
Cardiac Resynchr onization Therapy devices (CRT)  provides additional pacing 
options to optimize cardiac resynchronization therapy, based on the individual 
anatomy and needs of heart failure patients as well as the ability of  stimulating 
more than one LV pacing site within one cardiac cycle.  
Studies have show n that multiple point LV pacing via a QP LV lead may be an 
alternative approach to improve CRT response by delivering multiple LV pacing 
pulses, simultaneously recruiting a larger volume of myocardium  (Forleo et al., 
2016) . A recent IDE study from St. Jude  Medical showed that quadripolar multiple 
point LV pacing (MultiPointTM Pacing algorithm) was non -inferior to standard 
quadripolar biventricular (BiV) pacing  (Tomassoni et al., 2016) .  
The current protocol is designed  to demonstrate the effectiveness of th e MPP 
feature  in BIOTRONIK CRT -D systems  by converting a percentage of CRT non -
responders to responders.  
1.2.1 Published  Results for Multipoint LV Pacing  
Forleo et  al., 2016 evaluated the experience of the St. Jude Medical MPP -
capable CRT -D devices (Unify Quadr a MP or Quadra Assura MP) connected to a 
quadripolar LV lead (Quartet™).  A total of 507 patients in whom these devices 
had been successfully implanted were enrolled between August 2013 and May 
2015. The analyses included: (i) current clinical practices for  the management of 
such patients, and (ii) the impact of MPP on heart failure clinical composite 
response and on the absolute change in ejection fraction (EF) at 6 months. 
Multipoint pacing was programmed to ‘ON’ in 46% of patients before discharge. 
Method s of optimizing MPP programming were most commonly based on either 
the greatest narrowing of the QRS complex (38%) or the electrical delays 
between the electrodes (34%). Clinical and echocardiographic follow -up data 
were evaluated in 232 patients whom data  were available both at the baseline 
and the 6 -month follow -up examination. These patients were divided into two 
groups according to whether MPP was programmed to ‘ON’ (n = 94) or ‘OFF’ (n 
= 138) at the time of discharge. At 6 months, EF was significantly higher in the 
MPP group than in the biventricular -pacing group (39.1 ± 9.6 vs. 34.7 ± 7.6%; P 
< 0.001). Even after adjustments, early MPP activation remained an independent 
predictor of absolute increase in LVEF of ≥5% (odds ratio 2.5; P = 0.001). At 6 
    QP ExCELs  
 
Version: September 6 , 2019   Page 9 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
months, an improvement in clinical composite score was recorded in a greater 
proportion of patients with MPP -ON than in controls (56 vs. 38%; P = 0.009). On 
comparing optimal MPP and conventional vectors, QRS was also seen to have 
decreased significantly (P <  0.001) (Forleo et al., 2016) . 
The recent MultiPoint™ Pacing (MPP) IDE Study from St. Jude Medical showed 
that quadripolar multiple point LV pacing (MultiPointTM Pacing algorithm) was 
non-inferior to standard quadripolar biventricular pacing. The multicent er study 
enrolled and followed 506 subjects with a standard CRT -D indication who were 
implanted with a CRT -D system (Quartet™ LV lead with a Quadra CRT -D) 
capable of delivering either quadripolar biventricular pacing or MPP.  Quadripolar 
Bi-V pacing was act ivated at implant.  At 3 months post -implant, patients’ 
responder status was assessed, both responders and non -responders were 
randomized, and 1:1 randomization (Bi -V or MPP) was stratified by responder 
status.  The primary efficacy endpoint (freedom from sy stem -related 
complications through 9 months) was 93.2%, (97.5% lower confidence bound 
90.4%) was greater than the objective performance criterion of 75%.  The primary 
efficacy endpoint was met for both intention -to-treat and as -treated populations in 
381 ra ndomized patients (ITT, p=0.013 and as -treated, p=0.008, respectively).  
For patients in the MPP arm programmed with wide cathode spacing and the 
shortest intraventricular timing delay (5ms), MPP provided significantly higher 
clinical responder rate (betwee n 3 and 9 months) up to 87% (p=0.003 vs <30mm) 
and converted 100% non -responders to responders (p=0.006 vs <30mm).  
1.3 Devices 
This study utilizes the Ilivia 7 HF -T QP family and the Acticor /Rivacor  HF-T QP 
family CRT -D systems with an IS4 port for  connection to a Sentus OTW left 
ventricular  lead. The Sentus OTW QP L, Sentus OTW QP S, Sentus OTW QP 
S/49, and Sentus OTW QP L/49 will be further referred to as Sentus QP leads 
throughout this protocol.  
1.3.1 Sentus QP Lead  
The Sentus QP leads are 4.8 F transvenous, stero id-eluting, quadripolar 
coronary sinus leads intended for permanent pacing and sensing of the left 
ventricle during cardiac resynchronization therapy. The development of the 
Sentus QP lead is based on the predecessor product Corox OTW BP. The new 
elements of the development include two additional ring electrodes along the 
distal portion of the lead, a standard IS4 quadripolar lead connector and a small 
diameter.  
A single steroid collar with 0.5 mg dexamethasone acetate (DXA) is located 
proximal to the lead  tip. In the Sentus OTW QP L  and Sentus OTW QP S models 
the distance between LV1 -tip and LV2 -ring is 21 mm, between LV2 -ring and LV3 -
ring 20 mm and between LV3 -ring and LV4 -ring 20 mm. The Sentus OTW QP 
S/49 and Sentus OTW QP L/49 model s have shorter pole spacing for short target 
vein anatomies  with a distance of 21 mm between  LV1-tip and LV2 -ring, 15 mm 
    QP ExCELs 
 
Version: September 6 , 2019   Page 10 of 70 
CONFIDENTIAL: Do not copy or distribute without Sponsor approval 
between LV2 -ring and LV3 -ring, and 10 mm between LV3 -ring and LV4 -ring. The 
tip and ring electrodes are coated with fractal iridium. The tantal um and 
platinum/iridium conductor coil is insulated with silicone, and then externally 
coated with polyurethane. Polyurethane improves the gliding capabilities of the lead when advanced through a left ventricular lead delivery catheter and through the coronary vasculature. The Sentus QP leads can be positioned in the target 
vein by using a guide wire via the over- the-wire technique or by using a stylet. 
The Sentus QP has an outer diameter of 4.8 F and can be implanted with a CS lead delivery system. 
Four Sentus QP lead models are available: 
• Sentus OTW QP L and L/49 model s are passive fixation leads utilizing a 
2D dual -curve to achieve a stable position within the target vein.  
• Sentus OTW QP S and S/49 models utilize a bend in the distal end 
enhanced with a silicone screw to provide passive fixation within the target vein. 
 
Figure 1 : Sentus QP L ead Tip Design 
 
The Sentus OTW QP is available in three lengths; L- 75 (77 cm ), L-85 (87 cm) , 
and L-95 (97 cm ). All three length variants carry a green marker ring to identify 
them as left ventricular CRT leads. 
1.3.2 Pacing and Sensing Vector Options  
When connected to a CRT -D device with an IS4 LV port, the Sentus QP leads 
offer more options in pacing and sensing configurations as compared with 
conventional bipolar systems.  
The vectors are built between a cathode (From - ) to an anode electrode (To +). 
Besides the four consecutively numbered LV electrodes of the quadripolar LV 
    QP ExCELs  
 
Version: September 6 , 2019   Page 11 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
lead (LV1 tip, LV2 ring, LV3 ring, LV4 ring) the distal shock coil of the RV lead 
(RV c oil) or the ICD housing (CRT -D) can be used as additional anode 
electrodes for the LV pacing and sensing configuration.  This gives the Sentus QP 
leads a total of 12 LV pacing and 7 LV sensing vector options as described in 
Table 1. When implanted with an Acticor /Rivacor  family device, the Sentus QP 
LV lead offers 20 programmable pacing configurations.  
Table 1: LV Pacing and Sensing C onfiguration s 
Pacing Vectors  Sensing Vectors  
# From ( -) →  To (+)  # From ( -) → To (+)  
1 LV1 tip  → LV2 ring  1 LV1 tip  → LV2 ring  
2 LV1 tip  → LV4 ring  2 LV1 tip  → ICD 
3 LV1 tip  → RV coil  3 LV2 ring  → LV3 ring  
4 LV1 tip  → ICD 4 LV2 ring  → ICD 
5 LV2 ring  → LV1 tip  5 LV3 ring  → LV4 ring  
6 LV2 ring  → LV4 ring  6 LV3 ring  → ICD 
7 LV2 ring  → RV coil  7 LV4 ring  → ICD 
8 LV3 ring  → LV2 ring     
9 LV3 ring  → LV4 ring     
10 LV3 ring  → RV coil     
11 LV4 ring  → LV2 ring     
12 LV4 ring  → RV coil     
13 LV3 ring  → LV1 tip*     
14 LV4 ring  → LV1 tip*     
15 LV1 tip   → LV3 ring*    
16 LV2 ring → LV3 ring*     
17 LV4 ring  → LV3 ring*     
18 LV2 ring  → ICD*     
19 LV3 ring  → ICD*     
20 LV4 ring  → ICD*     
   *Pacing vectors are only available in the Acticor /Rivacor  family devices.  
The vectors  are chosen by selecting a catho de (From -) and an anode electrode 
(To +)  during device interrogation and programming  (Figure 2). 
    QP ExCELs  
 
Version: September 6 , 2019   Page 12 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Figure 2: Programmer Display of LV Pacing P olarity 
 
1.3.3 MultiPole Pacing (MPP) Description  
The MultiPole Pacing feature  of the Ilivia  and Acticor /Rivacor  HF-T QP family 
allows left ventricular pacing in two different vectors within a single cardiac cycle 
using the same quadripolar lead in order to improve synchronization of the 
contraction pattern.  Both left ventricular stimuli will either be before the right 
ventricular pace ( 1st LV – 2nd LV - RV) or after the right ventricular pace (RV -1st 
LV – 2nd LV ). The second LV stimulus  will only be capable of delivering the 
second pacing stimulus in the lef t ventricle; sensing and timing will not be 
affected by 2nd LV . The delay between the two left ventricular paces is 
programmable between 0 m s and 50 ms in 5 ms steps. All 20 currently approved 
pacing configurations are available for both pacing stimuli. Ho wever, the same 
pacing vector cannot be used for both stimuli. Pacing output and interventricular 
delays can be programmed independently. There is no change to the same 
parameter ranges available for pacing amplitude and pulse width (0.5 to 7.5 V 
and 0.4 t o 1.5 ms, respectively). The programmable parameters for the MultiPole 
Pacing feature are listed in Table 2. 
    QP ExCELs  
 
Version: September 6 , 2019   Page 13 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Table 2: Programmable Parameters for MultiPole Pacing  
Parameter  Programmable range  
LV MultiPole stimulation  OFF, 1st LV -2nd LV -RV, RV -1st LV -2nd LV  
LV stimulation amplitude ( 1st LV  and 2nd LV ) 0.5 to 7.5 V  
LV stimulation width ( 1st LV  and 2nd LV ) 0.4 to 1.5 ms  
Interval 1st LV – 2nd LV  0 to 50 ms  
Stimulation configuration ( 1st LV  and 2nd LV ) Any available pacing vector ( Table 1) 
MultiPole Pacing is programmable using programmer software that can be used 
with one of BIOTRONIK’s programmers, either the ICS 3000 (P950037/S035, 
dated May 18, 200 5) or the Renamic (P950037/S089, dated April 15, 2011). The 
user accesses the feature from the Bradycardia/CRT parameters tab  (Figure 3). 
Figure 3: Programming MultiPole Pacing  
As shown i n Figure 4 and Figure 5 the polarity, pulse amplitude, and pulse width 
for the two LV stimuli can be programmed independently . 

    QP ExCELs  
Version: September 6 , 2019   Page 14 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Figure 4: Programming 1st LV Stimulus  
 
Figure 5: Programming  2nd LV Stimulus  
 
Figure 6 and Figure 7 compare the timing of the ventricular stimuli depending on 
which chamber is selected to be initially paced.  When the right ventricle is paced 
first, the LV -LV delay starts after the V -V delay, whereas the V -V and LV -LV delays 
start simultaneously when the left ventricle is paced first.  
    QP ExCELs  
Version: September 6 , 2019   Page 15 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Figure 6: V-V Delay, LV First  
 
 
Figure 7: V-V Delay, RV First  
 
 
    QP ExCELs  
Version: September 6 , 2019   Page 16 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
2. STUDY DESIGN  
The QP ExCELs Study is a  multi -center , prospective , non -randomized clinical 
investigation  that includes a sub -study to satisfy an FDA required post -approval 
study of the Multi Pole Pacing feature (P MA P050023/S107) of the Ilivia HF -T QP 
family CRT -D system (PMA  P050023/S103)  or Acticor /Rivacor  HF-T QP family 
CRT-D system (PMA P050023/S125 ).  
Subjects enrolled into the QP ExCELs study are ‘provisionally enrolled’ in the MPP 
sub-study upon signing the Informed Consent Form. Once the subject meets all of 
the MPP sub -study inclusion and none of the exclusion criteria at the QP ExCELs 6 
month follow -up visit, or if a heart failure hospitalization  has occurred, the subject 
may continue  into the MPP sub -study, at which point they are ‘fully enrolled’  (as 
defined in  Table 3). No additional subject follow -up is required  once the QP 
ExCELs 6 month follow -up visit is completed, unless the subject is enrolled into the 
MPP sub -study.  
As pa rt of the MPP sub -study inclusion and exclusion criteria, a CRT responder 
status will be determined for all QP ExCELs subjects. The CRT Responder 
Classification at QP ExCELs 6 -month f ollow -up will be evaluated  by comparing the 
subject  status at the QP ExCE Ls Enrollment Visit and classified as documented 
below : 
• “Improved”:   
o No HF hospitalization has occurred, AND  
o NYHA class is improved  
• “Unchanged”:   
o No HF hospitalization has occurred, AND  
o NYHA class is unchanged  
• “Worsened”:  
o HF hospitalization has occurred,  OR  
o NYHA class is worsened  
Those subjects determined to have a CRT Responder Classification of  “Worsened” 
or “Unchanged” at the MPP enrollment visit  may continue into the  MPP sub -study  if 
all other inclusion and exclusion criteria are met . After enrollmen t into the MPP 
sub-study, the MPP feature will be programmed ON and an MPP optimization 
procedure may be performed for all subjects according to the site’s  preferred  
optimization method .  
Evaluation at the 3-month MPP  follow -up (90 ± 30 days post -MPP enrol lment)  and 
6-month MPP f ollow -up (180 ± 30 days post -MPP enrollment)  will include N YHA 
classification , Patient Global Assessment ( PGA ), and HF hospitalization status, in 
addition to collection of the MPP programming.  After completion of  the 6 -month 
MPP follow-up, subjects may be programmed to MPP or standard BiV pacing, per 
    QP ExCELs  
Version: September 6 , 2019   Page 17 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
physician discretion.  Subjects participating in  the MPP sub -study will be exited 
once the MPP sub -study 6 month visit has been completed.  
2.1 Objectives  
The primary objective of this clinica l investigation is to demonstrate that the MPP 
feature is effective by converting a percentage of C RT non -responders to 
responders . Each subject’s responder status will be assessed using a Clinical 
Composite Score (CCS) including three components: NYHA Cla ss, heart failure 
(HF) hospitalizations, and cardiovascular death  (Packer et al., 2001) . 
The MPP  sub-study  also includes three secondary endpoints.  
2.1.1 Primary Endpoint 1  
The purpose of primary endpoint 1 is to evaluate the CRT responder status with 
the MPP f eature within  the Ilivia 7 HF -T QP family CRT -D or Acticor /Rivacor  7 HF -
T QP family CRT -D system , compared to a pre -specified performance g oal. 
The associated hypothesis is evaluated based on a CCS determining a responder 
classification based on changes in  NYHA class, HF hospitalization, and 
cardiovascular death.  
A responder status will be derived classifying these subjects as “Improved”, 
“Worsened”, or “Unchanged” using the following definitions . 
Responder Classification at the 6 -Month MPP Follow -up (evalu ated compared to 
MPP enrollment visit ): 
• “Improved”:   
o No HF hospitalization or cardiovascular death, AND  
o NYHA class is improved  
• “Unchanged”:   
o No HF hospitalization or cardiovascular death, AND  
o NYHA class is unchanged  
•  “Worsened”:  
o HF hospitalization or car diovascular death has occurred, OR  
o NYHA class is worsened  
Ho: The proportion of subjects (P) who are classified as “Improved” is not superior 
to a performance goal (PG) of 3%.  
 PG ≥ P  
Ha: The proportion of subjects who are classified as “Improved” is superior to a 
performance goal of 3%.  
 PG < P  
    QP ExCELs  
Version: September 6 , 2019   Page 18 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
A rejection of the null hypothesis would indicate that the proportion of subjects 
classified as “Improved” is superior to 3%.  
2.1.2 Secondary Endpoint 1  
The purpose of Secondary Endpoint 1 is to evaluate adverse events that require 
additional invasive intervention to resolve, specifically related to the MPP feature of 
the Ilivia  or Acticor /Rivacor  HF-T QP family . These adverse events include any  
software issues related to MPP programming or any adverse event that occurs 
while MPP is enabled and that may be attributed to the use of the MPP feature.  
2.1.3 Secondary Endpoint 2  
The purpose of Secondary Endpoint 2 is to evaluate a modified CCS, determining  
a responder classification based on changes in NYHA class, Patient Global 
Assessment ( PGA), HF hospitalization, and cardiovascular death, where the PGA 
will ask subjects to assess how their overall status has changed since prior to 
receiving CRT thera py (markedly better, better, unchanged, worse, markedly 
worse).  
Modified Responder Clas sification (CCS + PGA) at the 6 -Month MPP  Follow -Up 
(evaluated compared to MPP enrollment visit ): 
• “Improved”:   
o No HF hospitalization or cardiovascular death, AND  
o Neither NYH A class is worsened or PGA is worsened (“worse” or 
“markedly worse”), AND  
o NYHA class is improved or PGA is improved (“better” or “markedly 
better”)  
•  “Unchanged”:   
o No HF hospitalization or cardiovascular death, AND  
o NYHA class is unchanged, AND  
o PGA is uncha nged (“unchanged”)  
•  “Worsened”:  
o HF hospitalization or cardiovascular death has occurred, OR  
o NYHA class is worsened or PGA is worsened (“worse” or “markedly 
worse”)  
2.1.4 Secondary Endpoint 3  
The purpose of Secondary Endpoint 3 is to evaluate the Responder Clas sification  
(as defined in Section 2.1.1 ) in which both “Improved” and “Unchanged” subjects 
will be classified as responders. At the time of enrollment into the MPP sub -study, 
MPP sub -study subjects have already b een found to have no change or worsening 
in their HF status with BiV pacing. Since HF is a chronic and progressive condition, 
    QP ExCELs  
Version: September 6 , 2019   Page 19 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
these subjects may be expected to continue to worsen during the MPP follow -up 
period or remain stable with careful management.  In this secondary endpoint, a 
status of “Unchanged” (in addition to “Improved”) during the MPP follow -up period 
will be considered a responder to MPP.  
2.1.5 Additional Data of Interest  
Additional information will be collected to characterize the study population, 
implanted system, and progress of the clinical investigation.  The data will be 
statistically analyzed, where appropriate.  Further data of interest will include:  
• Demographics, including age  and gender  
• Baseline New York Heart Association (NYHA) class  
• Histori cal left ventricular ejection fraction (LVEF), if obtained within 6 months 
prior to enrollment  
• Implanted devices, including pulse generator and other leads  
• Implantation site and, if available, implant approach  
• Sentus QP lead performance up to 6 months post -implant  including R -wave 
sensing, pacing impedance, and pacing threshold  
• Patient Global Assessment (PGA) at each visit  
• MPP programmed settings  
• Adverse events attributed to MPP feature  
• Device initial and final programmed settings  
• Methods utilized to optimi ze MPP, AV and/or V -V timing 
• Adverse events related to implant procedure, pulse generator, or implanted 
leads  
• Revisions to implanted system and reason for revision  
• Compliance to protocol requirements and study visit schedule  
2.2 Subject Status Definitions  
The subject status definitions utilized in this study  are provided in Table 3. 
    QP ExCELs  
Version: September 6 , 2019   Page 20 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Table 3: Subject Status Definitions  
Subject Status  Definition  
Provisionally enrolled  Subject has provided written informed consent but 
has not yet been screened against the MPP sub -
study specific inclusion and exclusion criteria . 
Provisionally enrolled subjects will become fully 
enrolled if they meet the MPP sub -study specific 
inclusion and  exclusion criteria , and  complete the 
MPP  Enrollment visit .  
Provisionally enrolled subjects will not be included in 
the analysis population for the study objectives; 
however, they may be included in analysis of 
additional data of interest.  
Screen Failure  Subject has signed consent, but at the time of 
consent it was identified the subject does not meet all 
inclusion/exclusion criteria,  
OR 
Subject consented prior to implant, but prior to 
implant the subject status changes.  
Subject will be exited and will not be included in the 
analysis population or count toward the enrollment 
maximum.  
Fully Enrolled  Subject meets all of the MPP sub -study specific 
inclusion criteria and none of the exclusion criteria, 
and completes  the MPP Enrollment visit.  
Fully enrolled subjects will be included in the analysis 
population for the study objectives, as well as in the 
analysis of t he additional data of interest.  
2.3 Study Size and Duration  
The MPP sub -study will enroll up to 110 subjects at up to 75 sites within the United 
States who are participating in the QP ExCELs st udy. Based on the previous 
sample size analysis for the post -approval QP ExCELs cohort, the sample size for 
the QP ExCELs study is 1754 and will remain unchan ged to support  continuation of 
the MPP sub -study  (QP ExCELs protocol version February 1, 2017 provides the 
justification and sample size analysis) .  
Subjects  that enroll  in the MPP sub -study will be followed  12 months  post-implant , 
while subjects that do not continue in the MPP sub -study will be followed for 6 
months post -implant.   
    QP ExCELs  
Version: September 6 , 2019   Page 21 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
2.3.1 MPP Sub -Study Sample Size Analysis  
The investigation is designed to limit the number of patients involved while still 
exposing the device to a sufficiently large patient population in order to ensure a 
representative and statistically meaningful sample.  
2.3.1.1  Primary Endpoint 1 Sam ple Size  
The estimated sample size requirements are based on a superiority comparison of 
the proportion of responders to a performance goal of 3%, chosen based on the 
assumption that any conversion of non -responders to responders is clinically 
relevant. A performance goal of 3% was chosen rather than 0% to account for 
variability (“noise”) around 0%, for example, due to infrequent subjects who are late 
responders to CRT or improve regardless of MPP. The expected result is 
estimated at a 10% conversion of no n-responders to responders.   
There is limited published data available for mid - to long -term follow -up CRT 
response with multiple point LV pacing in any population. The St. Jude Medical 
MultiPoint Pacing IDE Study (“St. Jude IDE study”, [STUDY_ID_REMOVED]) evalua ted CRT 
response based on a Clinical Composite Score (CCS) after 3 months of BiV pacing  
(Tomassoni et al., 2016; System Help Manual, St. Jude Medical) . Subjects were 
then randomized to the MultiPointTM Pacing treatment arm or to continue on with 
BiV pacing . The study showed that 70.1% of subjects were responders to 
MultiPointTM Pacing. However, both responders and non -responders after 3 months 
of BiV pacing were included in the MultiPointTM Pacing treatment arm. Additionally, 
the St. Jude IDE study only ran domized subjects with acute "equal or better" EA 
velocity time integral (VTI) with MultiPointTM Pacing vs. BiV pacing per 
echocardiogram at the 3 -Month Visit. There were 52 subjects that did not meet this 
criterion and were not randomized. Thus, subjects t hat may likely have not 
responded to multiple point LV pacing therapy were not randomized which certainly 
led to a higher response rate to MultiPointTM Pacing.  
BIOTRONIK proposes to allow enrollment of any QP ExCELs subject meeting non -
responder criteria ( “all-comer non -responders”) at the 6-Month  Follow -up into the 
MPP sub -study as it is not standard of care to perform echocardiograms on CRT 
subjects to determine if they are responding to standard CRT therapy. As such, we 
estimate that the proportion of no n-responders at 6-months that will be converted 
to responders at 12-months post-implant will be less than that observed in the St. 
Jude IDE study. There are three additional studies which have published results for 
CRT response with MPP measured via CCS or  NYHA improvement with mid - to 
long-term follow -up (6 to 12 months) (Forleo et al., 2016; Pappone et al., 2015; 
Zanon et al., 2016) . However, these studies also did not limit multiple point LV 
pacing treatment to non -responders, thus the results are not di rectly applicable to 
the proposed BIOTRONIK study design.  
Assumptions:  
• Study Design:  Superiority  Trial 
• Type I error (alpha):  0.025 (one -sided)  
    QP ExCELs  
Version: September 6 , 2019   Page 22 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
• Statistical power:  80% 
• Performance Goal: 3%  
• Expected: 10%  
A total of 90 evaluable subjects would be required to d emonstrate superiority to a 
performance goal of 3%.  
2.4  Interim Analysis  
An interim analysis will be performed on the primary endpoint when 50%  (n = 45)  of 
subjects  have completed participation in the MPP sub -study . An alpha spending 
function ( DeMets et al., 1994 ) will be incorporated to make adjustments on alpha 
for the interim and final analyses. Boundaries will be computed based on the 
O’Brien -Fleming method. The MPP sub -study will be terminated early and a final 
report will be prepared if the evidence of b enefit reaches significance of P<0.0026  
at the 50% interim analysis .  
Due to the conservative alpha spending for the interim analysis , the threshold for 
determining significance at the final analysis is impacted minimally, with a final 
nominal p -value requ ired for significance being 0.0224.  The required sample size is 
not affected to any meaningful extent by the interim analysis and the sample size 
for primary endpoint  1 remains unchanged (n = 90).  
Interim Analysis (50%), significance level, alpha=0.0026  
Type I Error, Final adjusted significance level, alpha = 0.0224  
2.5 Adjustments to Overall Sample Size  
Due to the inclusion of interim analyses, a  total of 90 evaluable subjects are 
required to demonstrate superiority to a performance goal of 3%. Assuming a 10%  
loss to follow -up rate during the study for reasons unrelated to the study ou tcomes, 
a total enrollment of 100 subjects  would be required to achieve an evaluable study 
population of 90 subjects.  
2.6 Data Analyses  
Descriptive statistics will be used to present  and summarize the data collected in 
the clinical study.  Frequency distributions and cross tabulations will be presented 
for discrete variables.  Means, standard errors, and ranges will be presented for 
continuous variables.  
Classification of “HF hospitaliz ation” and “cardiovascular death” events for use in 
primary endpoint 1, secondary endpoint 2, and secondary endpoint 3 analyses will 
be determined by a Clinical Events Committee (Section  5.1.1 .). 
For primary endpoint 1, t he lowe r, one -sided, exact 97.5% bound for the observed 
proportion of responders (“improved”) would have to exceed 3% for rejection of the 
null hypothesis.  Additional ly, descriptive  statistics  will be provided  for observed 
    QP ExCELs  
Version: September 6 , 2019   Page 23 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
changes in NYHA class and frequency tabu lations  provided  for the other 
components of the Clinical Composite Score.  
The AE -free rate calculated for secondary endpoint 1 will be based on the total 
number of subjects with at least one MPP related adverse event requiring 
additional inv asive interve ntion to resolve. For the secondary endpoint analysis, the 
AE classification, category, resolution, and relation to the MPP feature for each 
individual event will be determined by the Clinical Events Committee  (CEC)  
(Section 5.1.1 ). All adverse events which the CEC determines the event is related 
or possibly related to the MPP feature will be included in the secondary endpoint  1 
analysis. Adverse events with a final CEC adjudicated relation of not related or 
unknown will not cont ribute to or be included in the evaluation of the secondary 
endpoint.  
2.6.1 Replacement of Missing Data  
The last observation carried forward (LOCF) principle will be utilized for the 
analysis of NYHA Classification and Patient Global Assessment for primary 
endpo int 1 and secondary endpoints 2 and 3.  
Missing NYHA and patient global assessment data at either the enrollment or 
follow -up visits affects the number of subjects that can be included in the analysis.  
It is possible that subjects or study  personnel may eit her forget or choose not to 
answer one or more of the questions related to NYHA classification or patient 
global assessment.   
2.6.2 MPP Sub-Study Analysis Population  
The primary and secondary endpoint analyses will be conducted according to the 
intention -to-treat principle (IIT)  utilizing all available data from  fully enrolled  
subjects . Subjects  are expected to remain programmed with the MPP feature ON 
from MPP enrollment through the completion of the sub -study.  Subjects who have 
the MPP feature permanently turne d OFF prior to completion of the sub -study will 
be required to report a protocol violation ; however, these subjects will be included 
in the analysis population.  All available data from subjects that undergo a pulse 
generator change and no longer have an MP P eligible device will be included in the 
analysis. Subjects may have the MPP feature tempora rily turned OFF due to a lead 
revision procedure and these short durations with MPP will not be reported as a 
protocol violation.  
Any QP ExCELs subject that does not enroll into the MPP sub -study but receives 
MPP due to the physician’s determination will not be analyzed towards the MPP 
study endpoints.  
    QP ExCELs  
Version: September 6 , 2019   Page 24 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
3. PROTOCOL REQUIREMENT S 
3.1 Subject Population  
The subject  population  consists of  heart failure subject s with CRT -D indi cation 
according to clinical routine.  
Up to 1754  subject s will be enrolled in the clinical investigation. The investigator is 
responsible for screening all potential subject s and selecting those who are 
appropriate candidate s for enrollment in the QP ExCE Ls clinical study . The 
subject s selected for participation should be from the investigator’s general patient 
population with documented evidence of an indication for implantation of a 
BIOTRONIK CRT -D system  according to clinical routine  and according to th e 
inclusion and exclusion criteria described below.  Decision for implantation of the 
respective  BIOTRONIK devices  is based on medical decisions alone and should 
not be influenced by the possible enrollment to this clinical trial.   
The implanting physician is responsible for choosing the fixation and length variant. 
For the indications , we recommend following the respective current guidelines of 
the Heart Rhythm Society (HRS), the American College of Cardiology (ACC),  and 
the Am erican Heart Association (AHA) , as well as those of other national 
cardiology associations.  
Investigators are strongly encouraged to seek equal enrollment between men and 
women at their site. This will help ensure women are adequately represented in the 
study population and enable mean ingful analyses of results by gender.   
3.1.1 Indications  for Use 
The Sentus  OTW  QP left ventricular pacing lead is a 4.8 French (5 F introducer) 
quadripolar steroid -eluting lead intended for permanent implantation in the left 
ventricle via the coronary veins to provide pacing and/or sensing when used in 
conjunction with a compatible IS4 pulse generator.  
3.1.2 Contraindications  
Implantation of this lead is contraindicated in the following cases:  
• Coronary sinus anomalies  
• Tissue in the coronary sinus area  that has been da maged by an infarction  
• Any anomalies  of the venous system that preclude transvenous implantation 
of the lead  
• Patient cannot tolerate a single systemic dose of up to 0.5 mg  of 
dexamethasone acetate  (DXA)  
3.1.3 Inclusion C riteria 
All of the following inclusion cri teria have to be fulfilled for participation  in the QP 
ExCELs Study :  
    QP ExCELs  
Version: September 6 , 2019   Page 25 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
• Standard CRT -D indication according  to clinical routine  
• De novo  implantation or upgrade from existing ICD or pacemaker implant 
utilizing a BIOTRONIK Ilivia 7 HF -T QP family CRT -D system  or 
Acticor /Rivacor  HF-T QP family CRT -D system. feature with IS4 LV port and 
Sentus QP LV lead , that meets one of the following criteria:  
o Implant planned to occur after enrollment  
o Enrollment occurs within 30 days after implant and NYHA from within 
30 days prior to implant is documented in subject medical record  
• Patient is able to understand the nature of the clinical investigation and 
provide written informed consent  
• Patient is able and willing to complete all routine study visits at the 
investigational sit e up to  12 months  of follow -up 
• Able to understand the nature of the study and give informed consent  
• Available for follow -up visit s at the investigational site , including those 
specific to the MPP sub -study  
• Age ≥ 18 years  
At the time of MPP screening for inclusion into the MPP sub -study , additional 
inclusion criteria have to be fulfilled for participation:  
• Successfully implanted with a BIOTRONIK Ilivia  7 HF -T QP family CRT -D 
system  or Acticor /Rivacor  HF-T QP family CRT -D system. Successful 
implantation is defined as having at least two LV pacing vectors with a 
measured pacing threshold of ≤ 5.0 V @ any pulse width (allowing for a 
minimum 2.5 V safety margin) without phrenic nerve stimulation at the final 
progr ammed pacing output at the time of enrollment into the MPP sub -study.  
• CRT Responder Assessment classification as “Worsened” or “Unchanged”  
• Standard continuous biventricular (BiV) pacing from implant until MPP 
enrollment  
3.1.4 Exclusion C riteria 
None of the foll owing exclusion criteria can be fulfilled for  QP ExCELs  study 
participation:  
• Chronic atrial fibrillation  
• Contraindication to CRT -D therapy  
• Currently implanted with an endocardial or epicardial left ventricular lead or 
had prior attempt to place a left vent ricular lead  
• Cardiac surgical procedure, such as coronary artery bypass graft  or valve 
surgery that is planned to occur within 6 months after implant or ablation that 
is planned to occur within 90 days  after implant (ablations planned to occur 
prior to or at implant are not exclusionary)  
    QP ExCELs  
Version: September 6 , 2019   Page 26 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
• Expected to receive a heart transplant or ventricular assist device within 12 
months  
• Life expectancy less than 12 months  
• Participation in any other investigational  cardiac clinical investigation during 
the course of the stu dy 
• Presence of another life -threatening, underlying illness separate from their 
cardiac disorder  
• Pregnant or breast -feeding at time of enrollment  
At the time of MPP screening for inclusion into the MPP sub -study  none of the 
following exclusion criteria can  be fulfilled:  
• Development of c hronic atrial fibrillation  since  QP ExCELs  enrollment  
• Received MPP pacing prior to MPP sub -study enrollment  
3.2 Methods  
3.2.1 eCRFs 
During the course of the clinical investigation  all clinical procedures are performed 
according to cli nical routine. All parameters and measurements that are recorded 
within the clinical investigation  are described in this section and are documented on 
the appropriate  electronic Case Report Forms (eCRFs).  Information from 
electronically delivered sourc e data (e.g. programm er interrogations, adverse event 
documentation) will be uploaded to the appropriate eCRF, then captured and 
stored in a validated environment until the end of the study . The investigator will be 
required to use an electronic signature to a pprove the content of the data reported 
in the eCRFs.  
A QP ExCELs Study Termination eCRF should only be completed for early study 
termination. A QP ExCELs Study Termination eCRF is not required for subjects 
who complete the 6 month QP ExCELs visit and who  are not enrolled into the MPP 
sub-study. For subjects enrolled into the MPP sub -study, an MPP sub -study 
specific termination eCRF is required to record a study exit ; however, a QP 
ExCELs Termination eCRF is not required.  
BIOTRONIK , Inc.  will audit and mon itor the content of the eCRFs as described in 
Section  9. The required procedures and corresponding  time schedule  for eCRF 
completion  is described in Section 3.3  
All data have to be available for so urce data verification during monitoring 
conducted by  the sponsor. Subject s have to consent to the use of their medical 
data prior to enrollment by signing the informed consent form.  
3.2.2 Subject Demographics , Comorbidities and M edication s 
After the informed co nsent has been obtained, d emographic  information including 
year of birth, gender, height and weight should  be gathered for all subjects.  
    QP ExCELs  
Version: September 6 , 2019   Page 27 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Furthermore, details regarding illnesses, ECG diagnostics (if obtained within 6 
months prior to enrollment), most recen t LVEF, the assessment of the current 
NYHA class, the device therapy indication , comorbidities  and current 
cardiovascular medication should  be collected.  
3.2.3 Device S ettings 
The device programming must be medically reasonable. Recommended device 
settings for p articipation in this clinical trial are summarized in Table 4: 
Table 4: Recommended Device S ettings 
Parameter  Recommended  device settings  
BIOTRONIK Home Monitoring® ON 
Capture control LV lead  ON or ATM  
Pacing configuration  BiV 
LV MultiPole Pacing  OFF* 
*In order to  support the CRT responder assessment for enrol lment into the MPP sub -
study , the MPP feature should not be programmed ON prior to enrollment in the MPP 
sub-study .  
3.2.4 CRT Based Lead M easurements  
Documentation of the mean sensing amplitude, the pacing threshold and the 
impedance is required for the LV channel at beginning of device interrogation at 
implantation and the required  6 month follow -up post -implant . The pacing threshold 
can be measured eit her manually or triggered automatically.  
The LV pacing threshold is considered elevated  if the  threshold is greater than 2 .5 
V at 0.4 ms. The LV lead impedance is considered ‘ out of range ’ if a measurement 
is < 200 Ohms or > 3000 Ohms . The LV sensing thre shold is considered  ‘out of 
range ’ if a measurement is lower than 2  mV.  
The electronic programmer file with the stored measurements is used for source 
data verification.  
3.2.5 New York Heart Association (NYHA) Classification  
During the course of the study , the NYHA classification  will be utilized  for 
evaluation of the specific level of cardiac disease.  The NYHA will be evaluated at 
all protocol -defined follow -ups. The following bullets provide the definitions for each 
class:  
• Class I: Subject s with cardiac disea se, but without resulting limitation of 
physical activity. Ordinary physical activity does not cause undue fatigue, 
palpitation, dyspnea, or anginal pain.  
    QP ExCELs  
Version: September 6 , 2019   Page 28 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
• Class II: Subject s with cardiac disease resulting in slight limitation of 
physical activity. They are  comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal pain.  
• Class Ill: Subject s with cardiac disease resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary activ ity 
causes fatigue, palpitation, dyspnea, or anginal pain.  
• Class IV: Subject s with cardiac disease resulting in inability to carry on any 
physical activity without discomfort. Symptoms of cardiac insufficiency or of 
anginal syndrome may be present even at rest. If any physical activity is 
undertaken, discomfort is increased.  
The description for each of the classes was taken from the ACC/AHA Guidelines 
for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices (Gregoratos et 
al., 1998) .  
3.2.6 Patient Globa l Assessment (PGA)  
During the course of the MPP sub -study a PGA  will be given to assess how the 
subject’s overall status has changed since prior to receiving CRT therapy 
(markedly better, better, unchanged, worse, markedly worse).  It is important to 
minimi ze the influence on the respondent by limiting their interaction and verbal 
exchanges with spouses or other individuals who may affect results while the 
assessment form is being completed.   
3.3 Study Procedures  
Figure 8 provides an ov erview of the clinical study design. Details of subject 
eligibility requirements are noted in Sections 3.1.3  and 3.1.4 . Details of other 
specific study procedures and  collected data are noted in Section 3.2.  
 
 
 
 
 
 
 
 
 
 
 
    QP ExCELs 
Version: September 6 , 2019   Page 29 of 70 
CONFIDENTIAL: Do not copy or distribute without Sponsor approval 
Figure 8 : Clinical Study D esign 
Assessments of the lead performance are required at  the QP ExCELs  implan t and 
6 months follow-up visits. If circumstances pre vent the presence of the subject at 
the in-office follow -up visit, the reason for the missed follow- up has to be ind icated 
on the eCRF. In addition, interim evaluations related to adverse events, system 
revisions, or heart failure hospitalizations for inclusion into the MPP sub-study will 
be performed.  

    QP ExCELs  
Version: September 6 , 2019   Page 30 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Table 5: Required Visit Windows  for MPP Sub -Study 
Visit Type  Window  Days post -implant 
QP ExCELs 6 month follow -up/ MPP Enrollment * + 30 days  137 to 227  
3 month MPP follow -up ± 30 days  198 to 228  
6 month MPP follow -up ± 30 days  288 to 318  
*MPP Enrollment may also occur after 3 months post -implant (90 days post -implant) if the subject 
has a heart failure hospitalization.  
3.3.1 Overview of  Study Procedures  
Table 6 displays an overview about the study procedures at the different visits 
which are described in detail afterwards.  
Table 6: Procedures by Visit Type  
Procedures  Enrollment Implant 
 QP ExCELs 
and MPP 
sub-study 
Follow-up Interim 
Follow-up† 
Informed consent  x    
Verification of inclusion and 
exclusion criteria  x    
Demographic data and 
comorbidities  x    
NYHA class and heart failure 
symptoms  x*  x x 
ECG and ECHO values (if 
perform ed routinely)  x    
Co-morbidities  x    
Cardiovascular medication  x    
CRT-D implantation   x   
Implantation information   x   
Programming of device 
settings   x x x 
Standard device evaluation   x x x 
Adverse event reporting  x x x x 
Completion of eCRFs  x x x x 
† Interim follow -ups may be collected  when related to an AE , system revision  or for a heart failure 
hospitalization  for enrolment into the MPP sub -study . Implant information only needs to be collected 
if a system revision has occurred . 
* NYHA col lected within 30 days prior to implant if enrolled after implantation.  
    QP ExCELs  
Version: September 6 , 2019   Page 31 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
3.3.2 QP ExCELs Enrollment  
Prior to enrollment, the physician selects potential candidates which are eligible for 
the clinical study . If the  potential subject  meets all inclusion and exclusi on criteria 
(Section s 3.1.3  and 3.1.4 ), the potential subject  is asked to read and sign an 
Informed Consent Form. The potential subject should be provided with suffic ient 
time to consider participation in the trial.  
Subjects are  ‘provisionally  enrolled ’ into the MPP sub -study upon signing the 
Informed Consent Form and meeting the  inclusion/exclusion criteria at time of 
consent . All subjects e nrolled in the study must be entered in the subject 
enrollment log . The consent process should be  documented within the subject’s 
medical record.  
After informed consent has been obtained, the following data should be collected 
for baseline evaluation:  
1. Demographic characteristics  (year of birth, gender, height, weight)  
2. Device therapy indication  
3. ECG diagnosis , if routinely performed  
4. NYHA class  
a) For subjects enrolled prior to implant, current NYHA class as 
assessed by study personnel at the time of enrollment  
or 
b) NYHA cla ss obtained within 30 days prior to implant for subjects 
enrolled after implant.   
5. Most recent LVEF, obtained prior to implant  
6. Comorbidities and cardiac medications  
The E nrollment eCRF needs to  be completed using the data collected during the 
enrollment visit.  
3.3.3 Implantation  
Implantation  may occur  after enrollment of the subject  or may occur prior to 
enrollment if an NYHA assessment within 30 days prior to the implant date  is 
available in the subject’s medical record . For subjects implanted prior to  
enrollment, implant details and device data will be collected retrospectively.  
At implantation, the following data is collected:  
1. Implanted devices (manufacturer, model, serial number) , plus date of implant  
2. Implantation site, and if available, imp lant approach  
3. Sentus QP lead implant success  
5. Activation of the recommended device settings as listed in Section 3.2.3  
6. Sentus QP lead evaluation from implant procedure:  
    QP ExCELs  
Version: September 6 , 2019   Page 32 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
• Determine LV lead impedance  
• Determine LV mean R -wave sensing amplitudes  
• Determine LV pacing threshold at 0.4 ms pulse width for the pacing vector 
programmed at the end of implantation  
7. 
8. Device programming and settings at end of implantation procedure  
Store the electronic procedure data (including final device settings, 
measurements, episodes) from the BIOTRONIK programmer  
9. Complete the Implantation eCRF using data collected during implant and 
information from the end of procedure device evaluation  
10. Document any  reportable ad verse event  (e.g. phrenic nerve stimulation, high 
LV pacing threshold, etc.)  during the procedure on the respective eCRF.  
Please note:  
1. If the BIOTRONIK Ilivia 7 or Acticor /Rivacor  HF-T QP family CRT -D and /or 
Sentus QP LV lead  were not implanted , the su bject will be exited from the 
clinical investigation using a Study T ermination eCRF . 
2. In order to support the CRT responder assessment for enrollment into the 
MPP sub -study, the MPP feature should not be programmed ON prior to the 
MPP sub -study enrollme nt.  
3.3.4 QP ExCELs 6-month F ollow-up  
Six (6) months (± 45 days) after implantation,  subject s return to the investigational 
site for an in -office assessment of their implanted system. To support CRT 
Responder Assessment at 6 -months post -implant, QP ExCELs 6 -month follow -ups 
occurring prior to the visit window or more than 30 days after the visit window will 
not be allowed.  
The following data should be collected:  
1. Perform device interrogation:  
• Determine LV lead impedance  
• Determine LV lead R -wave sensing ampli tude  
• Determine the LV pacing threshold at 0.4 ms pulse width for the 
programmed pacing vector  
• Determine  LV pacing threshold @ any pulse width (allowing for a 
minimum 2.5 V safety margin) and document occurrence of phrenic 
nerve stimulation for additional  LV pacing vectors . 
2. Obtain NYHA classification and HF hospitalization status to determine CRT 
Responder Assessment classification  
    QP ExCELs  
Version: September 6 , 2019   Page 33 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
3. 
 Screen subject for MPP sub-study by confirming subject  meets all of the 
MPP sub -study specific inclusion criteria and  none of the MPP sub -study 
specific exclusion criteria (Section s 3.1.3  and 3.1.4 ). If the subject qualifies 
for the MPP sub -study, complete MPP sub -study enrollment p rocedures in 
Section 3.3.5 .  
4. Device programming and settings at end of follow -up. 
5. Store the electronic procedure data (including final device settings, 
measurements, episodes) of the BIOTRONIK programmer on an 
appropriat e USB flash drive . 
6. Complete the appropriate  Follow -Up eCRF.  
7. Document any  reportable adverse event (e.g. phrenic nerve stimulation, 
high LV pacing threshold, etc.)  using the respective eCRF.   
If subject  does not qualify for the MPP sub -study , no fu rther follow -up visits are  
required. A study termination eCRF  is not required.  
3.3.5 MPP Sub-Study Enrollment  
MPP sub -study enrollment occurs after a subject has been screened and 
determined to meet all MPP sub -study specific inclusion criteria and none of the 
exclusion criteria.  QP ExCELs subjects with a  heart failure hospitalization  will be 
considered to have a CRT Responder Assessment classification of worsened  and 
are eligible for the MPP sub -study. Subjects with a heart failure  hospitalization 
occurring pr ior to the 6  month post -implant  follow -up visit may be enrolled between 
3 and 6 months post -implant by completing an interim follow -up eCRF (Section 
3.3.8.1 ) or be enrolled at the  QP ExCELs  6 month follow -up visit  (Section 3.3.4 ).  
MPP optimization may be performed or not  performed per investigator discretion  at 
the time of enrollment into the MPP sub -study.  The investigator  will determine if 
MPP optimization will be  performed for each subject and whic h method will  be 
used (e.g. QRS width, electrical delay,  echocardiography, etc.). MPP programmed  
parameters may be adjusted as needed during the  follow -up period for MPP sub -
study subjects.   
After a patient has been screened and determined to be eligible f or the MPP sub -
study, t he following data will be collected:  
1. Turn MPP ON and collect MPP programmed settings  
2. Document MPP optimization method  
3. Obtain Patient Global Assessment  
4. Document any reportable Adverse Events  
5. Review and complete the appropriate eCRFs  
    QP ExCELs  
Version: September 6 , 2019   Page 34 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
The MPP feature must be programmed ON from MPP enrollment until the subject 
exits the sub -study.  Subjects who have the MPP feature permanently turned OFF 
prior to completion of the sub -study will be required to report a protocol violatio n.  
3.3.6 3-Month MPP Follow -up 
At a 3 -month MPP follow -up (90 ± 30 days post -MPP enrollment), subjects return 
to the investigational site for an in -office assessment of their heart failure status 
and implanted system.  
The following data should be collected:  
1. Collect MPP programmed settings  
2. Obtain NYHA classification and HF hospitalization status  
3. Obtain Patient Global Assessment  
4. Collect device initial and final programmed settings  
5. Document any reportable Adverse Events  
6. Review and complete t he appropriate eCRFs  
3.3.7 6-Month MPP Follow -up 
At the 6-month follow -up (180 ± 30 days post -MPP enrollment), subjects return to 
the investigational site for an in -office assessment of their heart failure status and 
implanted system.  
1. Collect MPP programmed settings  
2. Obtain NYHA classification and HF hospitalization status  
3. Obtain Patient Global Assessment  
4. Collect device initial and final programmed settings  
5. Document any reportable Adverse Events  
6. Review and complete the appropriate eCRFs  
7. Complete a study termination eCRF documenting MPP sub -study completion  
Following the 6 -month  MPP  follow -up, all subjects may be programmed to MPP or 
standard BiV pacing, per physician discretion.  
3.3.8 Interim F ollow-up 
Interim follow -ups may occur  anytime dur ing the clinical investigation; however,  
only those interim evaluations in support  of MPP sub -study enrollment due to a 
heart failure hospitalization between 3 and 6 m onths post -implant and those related 
to adverse event s or system revision s may be  collect ed in the clinical investigation. 
Interim follow -ups can be visits scheduled by physicians according to clinical 
routine, visits scheduled by the physician due to BIOTRONIK Home Monitoring® 
alerts or trends , or visits  initiated by the subject . 
    QP ExCELs  
Version: September 6 , 2019   Page 35 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
3.3.8.1  MPP Sub -Study Heart Failure Hospitalization  
Subjects with a heart failure hospitalization  meeting the definition in Section 6.1.4  
may be enrolled into the MPP sub -study b etween  3 and 6 month s post -implant by 
completing an interim visit eCRF . The following procedures are required:  
1. Obtain NYHA classification and HF hospitalization status  to determine CRT 
Responder Assessment classification  
2. Perform device interrogation:  
• Determine LV lead impedance  
• Determine LV lead R -wave sensing amplit ude  
• Determine the LV pacing threshold at 0.4 ms pulse width for the 
programmed pacing vector  
Determine  LV pacing threshold @ any pulse width (allowing for a minimum 
2.5 V safety margin) and document occurrence of phrenic nerve stimulation 
for additional LV pacing vectors . 
3. Screen subject for MPP sub -study by confirming subject  meets all of the 
MPP sub -study specific inclusion criteria and none of the MPP sub -study 
specific exclusion criteria (Section s 3.1.3  and 3.1.4 ). If the subject qualifies 
for the MPP sub -study, complete MPP sub -study enrollment procedures in 
Section 3.3.5  
3.3.8.2  Adverse event related interim follow -up 
For interim follow -ups related to an adverse event , the data collected on the  Interim 
Follow -up eCRF  is the same as the 6 and 12 month evaluations (Section 3.3.4 ). 
3.3.8.3  System Revision  
For interim evaluations that involve a system revision (even if the Sentus QP lead 
is not directly affected), the following data is required:  
1. Implantation procedure information (date of intervention, information about 
new implanted devices) . 
2 Revised device (manufacturer, model, serial number) . 
3. Sentus  QP lead measurements during procedure:  
• Dete rmine LV lead impedance  
• Determine LV lead R -wave sensing amplitudes  
• Determine LV pacing threshold at 0.4 ms pulse width for the pacing 
vector programmed at the end of intervention.  
4. Device programming and settings at end of intervention . 
    QP ExCELs  
Version: September 6 , 2019   Page 36 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
5. Store the electronic procedure data (including final device settings, 
measurements, episodes) of the BIOTRONIK programmer on  an 
appropriate USB flash drive . 
6. Complete the electronic System R evision  eCRF . 
7. Document any  reportable adverse event (e.g. phrenic ner ve stimulation, 
high LV pacing threshold, etc.)  during the procedure by using the 
respective eCRF.  
Please note:  
1. If prior to MPP  sub-study  enrollment, the BIOTRONIK Ilivia 7 HF -T QP family 
CRT-D system or Acticor /Rivacor  HF-T QP family CRT -D and/or Sentus QP 
LV lead  were explanted and not replaced with an MPP sub -study eligible 
system , the subject will be exited from the clinical investigation using a Study 
Termination eCRF . 
2. Whenever possible, BIOTRONIK devices that are explanted must be returned 
to BIOTRONIK , Inc.  for analysis.  
3.3.9 Study Termination  
A QP ExCELs Study Termination eCRF should only be completed for early study 
termination. Reasons for early study termination are described in Section 3.4.2 . A 
QP ExCELs Study Te rmination eCRF is not required for subjects who complete the 
6 month QP ExCELs visit and who are not enrolled into the MPP sub -study. For 
subjects enrolled into the MPP sub -study, an MPP sub -study specific termination 
eCRF is required to record a study exi t; however a QP ExCELs Study Termination 
eCRF is not required . 
3.4 Study Participation Expectations  
3.4.1 Point of E nrollment  
Subjects are  ‘provisionally enrolled’ into the MPP sub -study upon signing the 
Informed Consent Form and meeting the inclusion/exclusion cri teria at time of 
consent . 
3.4.2 Reasons for Study Termination  
Once a subject is enrolled and successfully implanted, every effort should be made 
to continue to follow the subject in the clinical investigation . However, it is inevitable 
that some subjects will de cline to participate further, change geographic location, or 
become non -compliant with the visit schedule.  
3.4.2.1  No implant a ttempt   
If BIOTRONIK Ilivia 7 HF -T QP family CRT -D system  or Acticor /Rivacor  HF-T QP 
family CRT -D system  and/or Sentus QP LV lead  was not  implanted , the subject  is 
exited . The reason  for study termination  must be provided.   
    QP ExCELs  
Version: September 6 , 2019   Page 37 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
3.4.2.2  Withdrawal of subject  consent  
Subject s may withdraw their consent for study participation at any time without 
stating the reason and without any unfavorable consequences . All data, which are 
collected until the date of withdrawal will be used for analysis . A Study T ermination 
eCRF  has to be completed  by the investigator in which the reasons for withdrawal 
should be documented  if willingly provided by the subject . 
3.4.2.3  Subject  death  
Personnel at the investigational site should notify BIOTRONIK as soon as possible 
concerning any subject death during the investigation.  This notification should 
include a completed study termination eCRF, death certificate, and a copy of the 
notific ation of the death sent to the IRB.  If a death certificate is not available, a 
detailed statement (death report) signed by the investigator should be written in 
addition to the termination eCRF. The death report should include all of the 
following, if avai lable:  
• date and time of death  
• place death occurred  
• identification of the rhythm at the time of death, if known (include any 
available documentation)  
• immediate cause of death  
• any other circumstances surrounding the death  
• whether it was device or procedure r elated  
All implanted devices that are involved with the investigational study should be 
removed and returned to BIOTRONIK.  
All deaths occurring while enrolled in the MPP study will be reviewed by the CEC.  
3.4.2.4  Sentus QP lead  or BIOTRONIK CRT -D extraction  
If prior to MPP enrollment  , any subject who has the BIOTRONIK Ilivia 7 HF -T QP 
family CRT -D system or Acticor /Rivacor  HF-T QP family CRT -D system  and/or 
Sentus QP LV lead  explanted and not replaced with an MPP sub -study eligible 
system  will be withdrawn from th e clinical investigation. After documentation of the 
system revision procedure (Section  3.3.8.3 ), a Study T ermination eCRF should be 
completed.  
Whenever possible, devices that are explanted must be returned to BIOTRONIK , 
Inc. for analysis . 
3.4.2.5  Lost to follow -up 
Subjects lost to follow -up are those for whom contact is lost despite the 
investigator’s best efforts to locate the subject. Study sites should attempt to 
contact these subjects in order to maintain study vis it compliance and all contact 
    QP ExCELs  
Version: September 6 , 2019   Page 38 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
attempts should be documented. At a minimum, the site should make two attempts 
to contact the subject by phone and one attempt by certified mail.  
In the event the subject cannot be contacted using the above methods, the subjec t 
is terminated from the clinical investigation by completing a Study T ermination 
eCRF.  
3.4.2.6  MPP Sub -Study Completion  
Subjects who complete the MPP 6 month follow -up visit will be exited with reason 
of MPP sub -study completion selected on the Study Termination  eCRF ; however a 
QP ExCELs Study Termination eCRF is not required.   
3.4.3 Date of Study T ermination  
The expected  study termination  for all subjects  should not be  earlier than the 6 
month follow -up visit.  
For all early  study termination s, the following rules app ly: 
• In case of withdrawal of consent, date of study termination is the  date of 
withdrawal of consent.  
• In case of subject  death, the date of study termination is the  date of death.  
• If subject  is lost to follow -up, date of termination is the  date of last 
documented contact with the subject . 
• If BIOTRONIK Ilivia 7 HF -T QP family CRT -D system or Acticor /Rivacor  HF-
T QP family CRT -D system and/or Sentus QP LV lead  was not implanted , 
the date of termination is the date of decision not to implant.  
• If prior to MPP enrollment,  the BIOTRONIK Ilivia 7 HF -T QP family CRT -D 
system  or Acticor /Rivacor  HF-T QP family CRT -D system  and/or Sentus QP 
LV lead  was explanted and not replaced with an MPP sub -study eligible 
system , the date of study termination is the date of system  revision.  
Study related procedures and documentation should end at the day of study 
termination  for the respective subject .  
    QP ExCELs  
Version: September 6 , 2019   Page 39 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
4. ADDITIONAL STUDY CONDITIONS  
4.1 IRB Approval  
Institutional Review Boa rd (IRB)  approval is required for  each study site  according 
to local requirements  and investigator  prior to participation in this clinical study. 
Subject  enrollment may not begin until both the IRB and BIOTRONIK , Inc.  have 
granted approval for the study site . IRB approval is also required throughout the 
duration of thi s clinical investigation.  If IRB approval is withdrawn, BIOTRONIK , Inc.  
must be notified by the investigator within 5 working days.  
4.2 Subject C onsent 
Subject  participation in this study is voluntary. All subject s must  sign an IRB 
approved Informed  Consent Form (ICF) prior to participation in the study . Subject  
informed consent must be obtained prior to  enrollmen t or any protocol related 
procedures.  Informed consent should be obtained in accordance with the FDA 
regulations (21CFR, Part 50).  The investigator is required to inform BIOTRONIK 
and the reviewing IRB within 5 days if any subject  was not appropriately consented 
to participate in the study.  In order to assist with the consent process, BIOTRONIK 
will provide a template patient consent form to investiga tional sites participating in 
the study.  
4.3 Data Collection  
4.3.1 Electronic Data Capture (EDC)  
MedNet Solutions Incorporated is a privately -held company that specializes in web -
based clinical data management technology. MedNet will host the EDC system and 
provide a secure environment that is accessible to authorized in dividuals through 
the internet.  BIOTRONIK , Inc.  will implement a study specific configuration using 
this software to meet the data collection requirements of the protocol. It is the 
platform for elect ronic case report form (eCRF) data entry, query management, and 
access to clinical data for parties authorized by BIOTRONIK , Inc.  
4.3.2 Electronic Case Report Forms  (eCRFs) 
Original data will be collected from each investigational site  and recorded into the 
EDC  system via completion of eCRFs . The investigator will be required to use an 
electronic signature to approve  the content of the data reported in the eCRFs.  
BIOTRONIK , Inc.  will audit and monitor the content of the eCRFs as described in 
Section 9. 
Information from electronically delivered source data (e.g. programmers ) will be 
captured and stored in a validated environment until the end of the study.  
    QP ExCELs  
Version: September 6 , 2019   Page 40 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
4.3.3 BIOTRONIK Home Monitoring® Data 
In the QP ExCELs s tudy, data of the study subjec ts will be accessible to the 
sponsor via transfer from the Home Monitoring Service Center during the course of 
study participation of the respective subject . BIOTRONIK Home Monitoring® data 
might be used for evaluation and publication if desired by the spo nsor.  
All data are transferred to the sponsor in a pseudonymized form. Data include s all 
information transmitted from the device (e.g. IEGMs, statistics, lead information).  
4.4 Confidentiality of Subject Data  
Information sent to BIOTRONIK , Inc. pertaining to s tudy subject s will be kept 
confidential at BIOTRONIK , Inc.  and i s subject  to audit  by IRB  and other regulatory 
authorities . For reporting purposes, data collected from U.S. sites will be shared 
with BIOTRONIK SE & Co. KG. Information shared with BIOTRONIK SE & Co. KG 
will be kept confidential.  Reports submitted  to physicians and data presented in  
publications of study results will not make any reference to subject name . 
In order to verify the study data and ensure study integrity, monitors from 
BIOTRONIK , Inc., authorized personnel from BIOTRONIK SE & Co. KG,  regulatory 
authorities , and the reviewing IRB may review and/or copy the study records.   
4.5 Data Quality Control  
BIOTRONIK , Inc.  will regularly review  study data. At any time, reports can be 
generated on e ntered or  missing data by BIOTRONIK , Inc.  or by approved 
research personnel at  each investigational site . The EDC system will be used to 
track received and expected visit data and eCRFs for each subject . This system  
also provides the capability to monitor the status, volume, and dis position of data. 
In addition, a ll study data will undergo extensive automatic edit and plausibility 
checks that provide  information to the investigational sites  to help improve and 
maintain data quality control procedures design ed to detect in accuracies and 
inconsistencies.   
4.6 Deviations from Clinical Investigation Plan  
The investigator is required to conduct this study  in accordance with the signed 
investigator agreement and clinical protocol. The investigator shall notify 
BIOTRON IK, Inc.  and reviewing IRB in writing no later than 5 working days after 
any significant deviation from the clinical protocol  that has occurred to pr otect the 
life or physical well -being of a subject in an emergency. Except in such emergency  
situations , prior approval by BIOTRONIK , Inc.  is required for significant deviations 
from the clinical protocol .  
BIOTRONIK, Inc. categorizes protocol non -compliance instances as either protocol 
violations or protocol deviations. Both protocol violations and deviations will be 
reported in the interim and final clinical progress reports.  
    QP ExCELs  
Version: September 6 , 2019   Page 41 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
4.6.1 Protocol Violations  
Protocol violations are defined as instances where the protocol requirements 
and/or regulatory guidelines were not followed, and are generally more serious in 
nature. Protocol violations are considered to potentially affect the scientific 
soundness of the study and/or the rights, safety, or welfare of subjects. Protocol 
violations include, but are not limited to, failure to obtain consent, and subject 
inclusion/exclusio n violations.  
4.6.2 Protocol Deviations  
Protocol deviations are defined as instances where the requirements of the 
protocol  were not followed  in such a manner whereby data is unusable or 
unavailable. Protocol deviations are less serious in nature and may not re quire IRB  
notification as long as they do not affect the rights, safety, or welfare of the study 
subject .  
Informed Consent documentation issues are also considered protocol deviations. 
These include but are not limited to incomplete ICF, missing dates for  signature(s), 
missing initials or illegible information, subject signature date completed by 
someone other than subject, utilization of an outdated or non -IRB approved ICF, or 
incomplete associated forms required at time of consent, etc. (this is not an 
exclusive list) . 
4.6.3 IRB Reporting of Non -Compliance  
The study site  must notify the reviewing IRB of all non -compliance issues per the 
IRB and protocol reporting requirements. At a minimum, all violations and non -
compliance issues related to informed consent an d informed consent 
documentation should  be reported to the IRB.  
In some instances, such as failure to obtain consent, the study site  should also 
seek guidance from the IRB to ensure the subject received appropriate information 
to consider her or his  participation in the study.  
The site should provide a copy of the IRB protocol noncompliance notification (as 
applicable) to BIOTRONIK.   
4.7 Subject Retention  
BIOTRONIK , Inc.  will provide additional tools to the  sites in an effort to minimize 
the number of subject s that are lost to follow -up. This  includes  an overview of each 
subject’s visit schedule, including the windows for each visit as they become due. 
The visit schedule reporting allows research person nel to become alerted to and 
track all study subjects that should be scheduled for upcoming study evaluations.  
In addition,  BIOTRONIK , Inc.  monitors will review subjects, including those that 
may be lost to follow -up, to ensure protocol and study visit  compliance . 
    QP ExCELs  
Version: September 6 , 2019   Page 42 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
4.8 Study Completion  
BIOTRONIK , Inc.  will notify the  U.S. study  site upon completion or termination of 
the clinical investigation  or of the investigator’s participation. BIOTRONIK , Inc.  will 
provide a Clinical Investigation Report  to each investigational site. BIOTRONIK , 
Inc. will also  determine which sites will have an on -site close out  visit and provide 
details on closure activities to all investigators to e nsure the investigator 
understands any applicable regulatory requirements, including those related to 
record retention.  
 
 
 
 
  
    QP ExCELs  
Version: September 6 , 2019   Page 43 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
5. STUDY OVERSIGHT  
5.1 Clinical Events Committee  
A Clinical Event s Committee (CEC) consisting of at least 3 independent 
Electrophysiologists or Cardiologists (with CRT experience) will be established to 
review and  adjudicate all MPP sub -study related events  (Section 5.1). Protocol 
defined adverse events that are not MPP sub -study related will be included in the 
clinical report based on site -reported information.   
The CEC will be blinded to the investigational  site and subject identity, and to 
minimize bias mem bers will not participate as investigators. The CEC will create a 
study specific charter defining the  adverse event  adjudication process, specifically 
detailing review guidelines along with appropriate response timelines.  
The Clinical Event s Committee is r esponsible for:  
• Endpoint adjudication of  adverse events meeting the criteria above  
• Adjudication meetings , as needed,  via telephone conference or face -to-face 
• Regular reporting of adjudication results to the sponsor  
The Clinical Event s Committee will be sup ported by members of the sponsor in 
pre-selection of device complications from non -device related adverse events (e.g. 
broken leg, headache, cancer) and in organizational tasks.  
5.1.1 Clinical Events Committee – MPP Sub -Study Events  
The QP ExCELs Clinical Events  Committee (CEC) described in Section 5.1 will 
adjudicate all adverse events that require additional invasive intervention to resolve 
which may be related to the MPP feature.  These events include any software 
issues related to MPP programming or any adverse event that occurs while MPP is 
enabled and that may be attributed to the use of the MPP feature.   The CEC will 
indicate whether the adverse event is related, possibly related, not related, or has 
an unknown relation to the MP P feature.    
In addition, the CEC will adjudicate all deaths reported while participating in the 
MPP sub -study and classify each death as cardiovascular, vascular, non -
cardiovascular/vascular, or unknown.   
The CEC will adjudicate all reported protocol -defined hospitalizations while a 
subject is enrolled in the MPP sub -study.  Hospitalization events will be classified as 
cardiovascular, vascular, non -cardiovascular/vascular, or unknown.  Additionally, 
hospitalizations classified as cardiovascular will be furth er classified as a HF 
hospitalization, non -HF hospitalization, or unknown. Hospitalization events reported 
by the investigator as part of the initial responder classification for enrollment into 
the MPP sub -study will not be adjudicated by the CEC.  
 
 
    QP ExCELs  
Version: September 6 , 2019   Page 44 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
6. ADVERSE EVENTS  
In the course of the clinical investigation , undesired medical events  can occur in 
participating subjects , which are called adverse events (AEs). All AEs shall be 
assessed by the investigator  and shall be documented and reported throughout the 
clinical investigation .  
The investigator shall submit to the sponsor all  reportable events using  the 
respective eCRFs provided within the EDC system.  
Based on literature research, the adverse e vents  listed in Appendix B may possibly 
occur as medical compl ications of a  cardiac rhythm management system implant . 
6.1 Definitions  
6.1.1 Definition of Adverse E vent 
An AE is defined  as any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in 
subjec ts, users or other persons whether or not related to the medical device. This 
includes:  
• Events related to the medical device or the comparator  
• Events related to the procedures involved  
• For users or other persons, this definition is restricted to events re lated to 
the medical devices.  
6.1.2 Definition of Adverse Device E ffect 
An adverse device effect (ADE)  is an AE that is related to the use of a  medical 
device. This includes any AE resulting from insufficient or inadequate instructions 
for use or the deployment , implantation, installation, or operation, or any 
malfunctioning of  a device and any event resulting from use error or from 
unintentional misuse of the device.  
Adverse events, which result from the required medical procedures involved, when 
implanting, u sing or testing the respective device, even if not directly related to the 
device (e.g. anesthetic complications, wound healing disturbances, lead 
perforation, etc.) are considered ADEs.  
Three categories for classification of relationship to the device and /or procedure 
are available:  
• Clearly not related: A relationship of the AE to the device and / or procedure 
can be excluded.  
• Possibly related: It cannot be excluded that there is a connection with the 
device under investigation and / or the procedure.  
• Clearly related:  A relationship of the AE to the device and/or procedure is 
likely/sure.  
    QP ExCELs  
Version: September 6 , 2019   Page 45 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
6.1.3 Serious AEs, ADEs  
AEs and ADEs are classified as serious  if one or more of the following 
consequences are fulfilled:  
• led to death  
• led to serious deterioration in the heal th of the subject, that either resulted in  
o a life -threatening illness or injury, or  
o a permanent impairment of a body structure or a body function, or  
o in-patient or prolonged hospitalization, or  
o medical or surgical intervention to prevent life -threatening i llness or 
injury or permanent impairment to a body structure or a body 
function.  
• led to fetal distress, fetal death or a congenital abnormality or birth defect.  
Note:  Planned hospitalization for a pre -existing condition, or a procedure required 
by the protocol, without serious deterioration in health, is not considered a serious 
adverse event.  
In-patient hospitalization is defined as at least one overnight stay (change of date) 
in a hospital. Events for which subjects are hospitalized for less than 24 hours  
without change of date  will not be documented as serious, unless one or more of 
the other serio usness criteria are fulfilled.  
6.1.4 Definition of Heart Failure Hospitalization  
Hospitalization for worsening heart failure is defined as a hospitalization that 
includes increased signs and/or symptoms of worsening heart failure requiring the 
administration or augmentation of intravenous or oral heart failure therapy (e.g., 
inotropes, diuretics, and/or vasodilators).   
A hospitalization classification will be based on  the primary admission diagnosis, 
not on the development of new events that occur during the hospitalization.   
For each hospital admission, the investigator will be requested to state whether or 
not the subject  experienced worsening heart failure at the ti me of admission or 
during the admission, and if so, whether or not this was the primary reason for 
admission or secondary to an obvious precipitating factor such as atrial fibrillation. 
The investigator will also be asked to state whether or not the subjec t received a n 
intravenous medication for heart failure including diuretics, vasodilators or inotropic 
agents or a substantial increase in oral diuretic therapy for heart failure.  
6.2 Reporting Adverse Events  
The investigator has to record any reportable advers e event  which occurs during 
study duration.  The adverse event will be classified according to the seriousness, 
the relation to the implanted  devices , and to the procedure. The investigator shall 
    QP ExCELs  
Version: September 6 , 2019   Page 46 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
report to the sponsor, by completing the appropriate eCRF, th e following types of 
events:  
• all adverse events related to or possibly related to  the implanted system  
• any major adverse events related to procedures involved with implanting, 
using, or testing the implanted system  (examples  are provided  in Section 
6.3.1  and definitions  are provided  in Appendix A: Definition of Terms ) 
• any adverse device effects , regardless of severity  
• any cardiovascular hospitalization s and any other hospitalizations in  which 
cardiovasc ular symptoms  occur  during participation in the MPP sub -study  
(Section 6.3.2  provides  definitions)  
• most recent heart failure hospitalization  that occurs after eligible system 
implant and before MPP sub -study enrollment (if subje ct participates in the 
MPP sub -study;  Section 6.1.4  provides  definition)  
• all adverse events that require  additional invasive intervention to resolve, 
specifically related to the MPP feature of the CRT -D that occur during 
partici pation in the MPP sub -study  (examples are provided in Section 6.3.3 ) 
Events will be reported on an Adverse Event eCRF. Events should be reported as 
information is available, even if this results in an incomplete eCRF.  The invest igator 
must  follow -up all ongoing reportable events  either as long as the subject  
participates in the clinical investigation , the clinical investigation is terminated , or 
until the event has been resolved, whatever comes first.  
The investigator must charac terize each event by a single primary diagnos is. The 
primary diagnos is may describe an event consisting of several clinically 
recognizable features, symptoms or secondary diagnoses.  Note: The observed 
symptoms and secondary diagnoses must be properly docum ented in the 
respective eCRF.   
Multiple events may occur simultaneously in one subject. For each medically 
independent event with a primary diagnos is an individual report must be provided.  
In addition, the action taken/ treatment should also be provided wit h any supportive 
documentation available.  
The investigator has to ensure that all relevant information is available. This also 
includes information from other parties (family, other hospitals , etc.).  
If a patient dies during the clinical investigation , the investigator shall document the 
cause of death, circumstances and place of death  (as defined in Section 3.4.2.3 ). 
All actions taken, which were initiated to gain further information must be 
documented in writing and provided to BIOTRONIK , Inc.  
Investigators are required to adhere to applicable regulations and reviewing IRB 
reporting requirements for adverse events.  
    QP ExCELs  
Version: September 6 , 2019   Page 47 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
6.3 Reportable Adverse Events  
6.3.1 Lead, System, and Procedure Related Event Examples  
The following are examples of potent ial reportable adverse events and do not limit 
the required adverse event reporting as defined in Section 6.2. 
Examples of reportable lead related events   
• Ablation sequelae (such as lead 
dislodgement or damage during an 
ablati on) 
• Cardiac perforation occurring post 
implant  
• Clinical lead failure  
• High pacing threshold  
• Extracardiac stimulation (e.g. phrenic 
nerve stimulation)  
• Electrical lead failure  
• Intermittent capture  
• Lead abrasion  
• Lead dislodgement or migration (not 
occurring du ring a procedure)  
• Lead impedance out of range, high 
impedance  
• Lead impedance out of range, low 
impedance   • Lead fracture or insulation damage  
• Lead undersensing  
• Lead -related thrombosis  
• Loss of sensing  
• No capture  
• Mechanical lead failure  
• Muscle or nerve stimul ation  
• Twiddler’s syndrome  
• Unsuccessful Sentus QP lead implant   
• Lead repositioned, explanted, or replaced for 
any other reason  
Examples of reportable system or pulse generator related events  
• Device extrusion  
• Device migration  
• Inappropriate detection of 
arrhythmias  
• Inappropriate therapy or shocks  
• Inability to defibrillate or pace  
• Myopotential sensing  
• Pacemaker mediated tachycardia   • Premature battery depletion  
• Pulse generator failure  
• Shunting current or insulating myocardium 
during defibrillation with interna l or external 
paddles  
• Skin erosion  
• Pulse generator repositioned, explanted, or 
replaced for any other reason  
Examples of reportable major implant related events  
• Air embolism  
• Anesthetic complications  
• Allergic reaction to components used 
at implant or duri ng lead testing,  
• or to components of the lead  
• Arrhythmias associated with implant  
• Arteriovenous fistula  
• Body rejection phenomena  
• Cardiac perforation with or without 
tamponade associated with lead 
implant  
• Chronic nerve damage  
• Coronary sinus dissection  
• Dama ge to lead during a procedure  
• Fluid accumulation  
• Heart valve damage  
• Major Hematoma  • Infection  
• Keloid formation/fibrotic tissue formation  
• Lead dislodgement of chronic leads that 
occurs during a proced ure 
• Loose set -screw  
• Myocardial damage  
• Non-healing pocket dehiscence or other 
wound healing disturbance  
• Pericardial effusion  
• Pericarditis  
• Phlebitis  
• Pleural effusion  
• Pneumothorax associated with lead implant  
• Pulmonary embolism associated with the 
implant pro cedure  
• Respiratory arrest  
• Venous occlusion associated with the 
    QP ExCELs  
Version: September 6 , 2019   Page 48 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
• Hemothorax  
• Incorrect lead connection with pulse 
generator  implant procedure  
 
Please note:  Phrenic nerve stimulation is an expected event during left ventricular 
threshold testing. As the Sentus QP lead allows for measurements in up to 20 
different v ectors, phrenic nerve stimulation might be a common observation in this 
study. Therefore phrenic nerve stimulation during threshold testing is only 
considered a reportable adverse event if serious medical symptoms occur.  
6.3.2 Reporting Hospitalizations  
To elimi nate possible bias at the site level  related to possible endpoint events of 
the MPP sub -study , adverse events requiring hospitalization for any cardiovascular 
hospitalizations and any other hospitalizations in which cardiovascular symptoms 
occur  will be co llected  while subjects are enrolled in the MPP sub -study . Each 
hospitalization will be adjudicated to determine whether it meets the MPP sub -
study endpoint criteria as a heart failure hospitalization by the C linical Events 
Committee (CEC).  
BIOTRONIK  will b e responsible for verifying completeness of the initial reported 
event  and coordinating with sites to obtain any missing or additional source 
documentation required by the CEC to adjudicate the case.  Additional 
documentation will be requested from the enro lling site as needed. The hospital 
report should include the followin g, if available:  
• Discharge summary  
• History and ph ysical and admission summary  
• Diagnos tic and laboratory test results  
• Chest X -ray, echocardiography, ultrasound or other imagi ng test result s, as 
appropriate  
• Consultations, operation reports, progress notes and discharge summaries 
from the subject medical  records  
• Investigator descript ion and assessment of the event  
6.3.3 MPP Feature Related Adverse Events  
All adverse events that required additional invasive intervention to resolve, 
specifically related to the MPP feature of the CRT -D will be reported. These 
adverse events include any software issues related to MPP programming for any 
adverse event that occurs while MPP is enabled and that may be attr ibuted to the 
use of the MPP feature.  
    QP ExCELs  
Version: September 6 , 2019   Page 49 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
6.4 Sponsor Reporting  
To ensure  reporting  requirements are met  during the study , adverse event 
informati on reported for all study sites will be reviewed  by BIOTRONIK  to ensure 
specific reporting requirements are met.  
 
    QP ExCELs  
Version: September 6 , 2019   Page 50 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
7. OTHER INSTITUTIONS AND PHYSICIANS  
This clinical study  is not transferable to other institutions attended by the 
investigator unless prior approval is obtained from both BIOTRONIK , Inc.  and the 
appropriate IRB. Only approved investigators are authorized to par ticipate in the 
clinical investigation . However, there are certain situations where an investigator 
might not be immediately available to provide the necessary medical care for a 
subject  enrolled in the clinical investigation  (such as  a subject emergency r oom 
visit for medical treatment)  in these instances a protocol deviation will not be issued 
and all available data will be utilized . 
In case technical support is needed the service hotline of BIOTRONIK , Inc.  is 
available 24 hours a day. Phone: 1 -800-547-0394. 
    QP ExCELs  
Version: September 6 , 2019   Page 51 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
8. RISKS AND BENEFITS  
8.1.1 Potential Benefits  
The clinical benefit of the Ilivia 7 HF-T QP family or Acticor /Rivacor  HF-T QP family 
CRT-D system , is similar to that of standard CRT -Ds. Subjects taking part in th is 
study may receive additional examinations of their CRT system.  
Although the participating study subjects might benefit from the new CRT -D system 
with MPP feature, currently there is only limited benefit for enrolled study subjects.  
Studies have shown that multiple point LV pacing via a QP LV lead may  be an 
alternative approach to improve CRT respons e by delivering multiple LV pacing 
pulses,  simultaneously recruiting a larger volume of myocardium  (Forleo et al., 
2016) . A recent IDE study showed that quadripolar multiple point LV pacing was 
non-inferior  to standard  quadripolar biventricular pacing  (Tomassoni et al., 2016) . 
The medical community, as well as future subjects, may benefit from these study 
results, which will enable a better understanding of the safety and efficacy of the 
MPP feature.  
8.1.2 Potential Risks  
All devices, device leads, device programmers, and Home Monitoring® systems 
included in the QP ExCELs study are legally marketed and being prescribed by 
physicians according to FDA approved indications for use. There are no new  
known  risks associa ted with participation in this study. Please refer to the product 
manuals for risks assoc iated with the implanted leads or CRT -Ds.  
During the course of this study subjects may experience potential adverse    the 
evaluation of the relation between the adve rse event and the  MPP feature . The 
date of the adverse event and  resolution must be recorded. W hen an adverse 
event is noted in  the EDC system , corrective action will also be provided with any 
supportive documentation available. Corrective actions may incl ude, for example: 
drug therapy change s, programming changes , lead repo sitioning , new lead 
implant s, or CRT -D explant .  
Study sites may report adverse events through MedWatch, FDA’s adverse event 
reporting tool for market -released devices. As defined in BIO TRONIK’s internal 
procedures, these adverse events may be reported by BIOTRONIK through 
manufacturer’s MedWatch reports.  
Another research related risk is the potential loss of confidentiality that is minimized 
by PHI redaction in the study.  
 
    QP ExCELs  
Version: September 6 , 2019   Page 52 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
9. MONITORING  
9.1 Summary 
The responsibility of BIOTRONIK , Inc.  as sponsor is to ensure protocol and 
regulatory compliance through proper monitoring of the clinical investigation  in 
sites. As the investigator, the physician is responsible for conducting the clinical 
investigat ion in accordance with the signed Investigator Agreement, the study 
protocol, applicable laws, a nd FDA and/or local regulations  and any conditions of 
approval imposed by  the reviewing IRB . The principal  investigator must also accept 
responsibility for all aspects of the clinical investigation including the actions of any 
sub-investigators participating in the clinical investigation at the site.  
BIOTRONIK utilizes a risk -based monitoring strategy consistent with FDA’s 
Guidance for Industry:  Oversight of Clin ical Investigations – A Risk -Based 
Approach to Monitoring, August 2013. Risk-based monitoring starts with performing 
a study risk assessment of the identified critical data and processes. The resulting 
monitoring plan focuses on targeted source data verifi cation and trend analyses to 
improve oversight and data quality, while integrating predefined triggers for  
additional on -site monitoring. The detailed QP ExCELs risk -based monitoring plan 
developed by BIOTORNIK, Inc. focuses on a combination of monitoring visits and 
centralized  monitoring.  
Monitors will conduct monitoring visits periodically during the clinical investigation 
in accordance with the monitoring plan. Sites  are required to support these 
monitoring visits and the study monitoring effort. Monito ring visits will also provide 
an assessment of the continued acceptability of the facilities to continue 
participation in the study.  
Centralized monitoring is conducted via investigator signed  electronic case report 
forms (eCRFs) through the source data v erification of source documents uploaded 
to the eCRF.  Some examples of data that may be monitored remotely include: 
informed consent forms, enrollment , eligibility, implant, study termination, device 
data and adverse events reported in the EDC system. Site s are required to support 
centralized monitoring by providing source documents to BIOTRONIK in order to 
source data verify data reported in the EDC system and resolving queries in a 
timely manner. Uploaded s ource documents should meet ALCOA -C principles of  
attributable, legible, contemporaneous, original, accurate , and complete . It is 
critical that the fully executed informed consent form and all necessary source 
documentation are uploaded to the EDC in a timely manner . 
The entries in the eCRF will be revie wed and source data verified by monitors 
(authorized BIOTRONIK , Inc.  personnel, or by authorized BIOTRONIK , Inc. 
designees) to ensure that the investigator and the clinical investigation team 
conducts the clinical investigation in accordance with the clinical investigation 
protocol  and applicable FDA and local laws and regulations to ensure adequate 
protection of the rights, safety and wellbeing of subjects and the quality and 
integrity of the resulting data.  In addition, BIOTRONIK, Inc. may require the 
    QP ExCELs  
Version: September 6 , 2019   Page 53 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
presence of personnel from BIOTRONIK, Inc. at implant and/or follow -up visits 
outlined in this protocol in order to assist the investigator and other site personnel.  
9.2 Monitors 
Monitors are trained, qualified, and designated by BIOTRONIK , Inc.  management 
to ove rsee the progress of a study at the clinical site. Additional monitors may be 
appointed as necessary.  
If a monitor becomes aware that an investigator is not complying with the signed 
Investigator Agreement, the study protocol, applicable laws, a nd FDA and /or local 
regulations  and any conditions of approval imposed by  the reviewing IRB , the 
monitor is obliged to notify BIOTRONIK , Inc.  study management. BIOTRONIK , Inc.  
will evaluate the non -compliance and issue corrective actions, discontinue 
enrollment or a s a last measure close the clinical investigation site.  
    QP ExCELs  
Version: September 6 , 2019   Page 54 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
10. RECORDS AND REPORTS  
10.1 Investigator Records  
Investigators are required to maintain the following accurate, complete and current 
records relating to this study:  
• All correspondence relating to the study wi th another investigator, an IRB, 
BIOTRONIK , Inc. , a monitor, or any regulatory agency (e.g., a letter sent 
from the investigator to the IRB)  
• All clinical forms and documentation, including:  
o A copy of all signed Informed Consent F orms 
o All procedure and visit report forms, including supporting documents  
o Records of any adverse device effect, including supporting 
documentation  
o Records pertaining to subject deaths during the study  
o Protocol with d ocumentation and rationale for any deviations from the 
clinical pro tocol  
o Any other records required by BIOTRONIK , Inc.  
The investigator must retain records related to the study according to FDA 
regulations and IRB requirements . 
10.2 Investigator Reports  
Investigators are required to prepare and submit to BIOTRONIK , Inc.  the fo llowing 
complete, accurate and timely reports on this study, when necessary:  
• Notification of a subject death during the study  
• Notification of the withdrawal of IRB approval  
• Annual progress reports prepared for the IRB  
• Notification that informed consent wa s not obtained from a subject  
• Final summary report prepared for the IRB  
• Any other information upon the request of an IRB, regulatory authority , or 
BIOTRONIK , Inc.  
Table 7 outlines  the responsibilities, including time constraints, for submitting the 
above reports.  
    QP ExCELs  
Version: September 6 , 2019   Page 55 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Table 7: Investigator  Reports  
Type of Report  Prepared by  
Investigator for:  Time Constraints of Notification  
Subject death during 
study  BIOTRONIK, Inc. , 
IRB As soon as possible and as required by 
reviewing IRB  
Subject withdrawal  BIOTRONIK, Inc.  Within 5 working days after notification of 
withdrawal  
Withdrawal of IRB 
approval  BIOTRONIK, Inc.  Within 5 working days of receipt of notice 
of withdrawal of approval  
Progress report(s)  BIOTRONIK, Inc., 
IRB Submitted no less than yearly  
Significant deviations 
from study plan  BIOTRONIK, Inc. , 
IRB Within 5 working days after emergency to 
protect life or physical well -being of 
subject, otherwise prior approval by 
BIOTRONIK, Inc. is  required  
Informed consent not 
obtained  BIOTRONIK, Inc.,  
IRB Within 5 working days of occurrence  
Final summary report  BIOTRONIK, Inc.,  
IRB Within 3 months after completion or 
termination of the study  
10.3 Sponsor Records  and Reports  
BIOTRONIK , Inc.  will maintain the following records:  
• All correspondence with the investigator(s), IRBs, and FDA  that pertains to 
the study  
• Investigator agreements, financial disclosures, and current curriculum vitae  
• Name and address of each investigator and each IRB that is involved with 
the investigation  
• Adverse events  
• Adverse device effects  
• Electr onic Case Report F orm data  
• Confirmation of c ompleted subject informed consent forms  
• Clinical investigation protocol  and report of prior investigations  
• Screening visit reports  
• Monitoring reports  
• Clinical progress reports  
• Statement of the extent to which the good manu facturing practice regulation 
in part 21  CFR 820 will be followed in manufacturing the device  
    QP ExCELs  
Version: September 6 , 2019   Page 56 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
BIOTRONIK, Inc. is responsible for preparing the following reports, when 
necessary:  
Table 8: Sponsor Reporting Responsibilities  
Type of Report  Prepared by  
BIOTRONIK for  Time Constraints  of Notification  
Withdrawal of IRB  
approval  FDA, all reviewing 
IRBs,  participating 
investigators  Within 5 working days of receipt of 
notice of withdrawal of approval  
Withdrawal of FDA 
approval  Reviewing IRBs,  
participating 
investigators  Within 5 wo rking days  
Progress r eport  FDA, all reviewing 
IRBs  Submitted at least annually  
Final r eport  FDA, all reviewing 
IRBs, participating 
investigators  Notification within 30 working days of 
the completion or termination of the 
investigation. A final report will be 
submitted within 6 months after 
completion or termination of the study . 
 
 
 
    QP ExCELs  
Version: September 6 , 2019   Page 57 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
11. REFERENCE S 
Bradycardia and Tachycardia Devices Merlin™ Patient Care System Help Manual, 
St. Jude Medical, Sylmar, CA, 2016, pp. 418 -431, https://manuals.sjm.com  
Bristow,M.R., Saxon,L.A., Boehmer,J., Krueger,S., Kass,D.A., De Marco,T., 
Carson,P., DiCarlo,L., DeMets,D., White,B.G. et al. (2004). Cardiac -
resynchronization therapy with or  without an implantable defibrillator in advanced 
chronic heart failure. N. Engl. J. Med. 350, 2140 -2150.  
Cabrera -Bueno,F., Rodriguez,J.A., de Ros,J.O., Fernandez -Lozano,I., 
Guerrero,J.J.G., Fernandez de la Concha,J., Madrid,A.H., Tolosana,J.M., 
Asensi,J.O ., Cordero,A.B. et al. (2013). Improvement in hemodynamic response 
using a quadripolar LV lead. Pacing Clin. Electrophysiol. 36, 963 -969. 
Crossley,G.H., Exner,D., Mead,R.H., Sorrentino,R.A., Hokanson,R., Li,S., and 
Adler,S. (2010). Chronic performance of a n active fixation coronary sinus lead. 
Heart Rhythm 7, 472 -478. 
DeMets DL, Lan KK. (1994). Interim analysis: the alpha spending function 
approach. Stat Med 13,1341 -56. 
Dickstein,K., Cohen -Solal,A., Filippatos,G., McMurray,J.J., Ponikowski,P., Poole -
Wilson, P.A., Stromberg,A., van Veldhuisen,D.J., Atar,D., Hoes,A.W. et al. (2008). 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 
2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart 
Failure 2008 of the  European Society of Cardiology. Developed in collaboration 
with the Heart Failure Association of the ESC (HFA) and endorsed by the 
European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29, 2388 -
2442.  
Dickstein,K., Vardas,P.E., Auricchio,A., D aubert,J.C., Linde,C., McMurray,J., 
Ponikowski,P., Priori,S.G., Sutton,R., van Veldhuisen,D.J. et al. (2010). 2010 
Focused Update of ESC Guidelines on device therapy in heart failure: An update of 
the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure and the 2007 ESC guidelines for cardiac and resynchronization 
therapy Developed with the special contribution of the Heart Failure Association 
and the European Heart Rhythm Association. Eur. Heart J. 31, 2677 -2687.  
Forleo GB , Santini L, Giammaria M, Potenza D, Curnis A, Calabrese V, Ricciardi 
D, D’agostino C, Notarstefano P, Ribatti V, Morani G, Mantica M, Di Biase L, 
Bertaglia E, Calo L, Zanon F. Multipoint pacing via a quadripolar left -ventricular 
lead: preliminary results from the Italian registry on multipoint left -ventricular pacing 
in cardiac resynchronization therapy (IRON -MPP). Europace 2016, 19, 1170 -1177.  
Goetze,S., Defaye,P., Bauer,A., Merkel,M., Bizeau,O., Treusch,S., Contzen,K., 
Juenger,C., and Winter,J. (2013). Phrenic nerve stimulation in CRT patients and 
benefits of electronic lead repositioning: the ERACE trial. J Interv Card 
Electrophysiol 38, 1 -9. 
    QP ExCELs  
Version: September 6 , 2019   Page 58 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Gregoratos G, Cheitlin MD, Conill A et al. (1998). ACC/AHA 1998 Guideline for 
Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: a report of the 
American College of Cardiology/American Heart Association Task Force on 
Practice. J Am Coll Cardiol 31, 1175 -1209.  
Gurevitz,O., Nof,E., Carasso,S., Luria,D., Bar -Lev,D., Tanami,N., Eldar,M., and 
Glikson,M. (2005) . Programmable multiple pacing configurations help to overcome 
high left ventricular pacing thresholds and avoid phrenic nerve stimulation. Pacing 
Clin. Electrophysiol. 28, 1255 -1259.  
Hansky,B., Vogt,J., Gueldner,H., Heintze,J., Lamp,B., Horstkotte,D., and  
Koerfer,R. (2006). Left ventricular pacing and CRT. What CV fits into which vein? 
Herzschr. Elektrophys 17, I/14 -I/19. 
Lloyd -Jones,D., Adams,R.J., Brown,T.M., Carnethon,M., Dai,S., de Simone,G., 
Ferguson,T.B., Ford,E., Furie,K., Gillespie,C. et al. (2010) . Heart disease and 
stroke statistics --2010 update: a report from the American Heart Association. 
Circulation 121, e46 -e215.  
Metha,P.A., Shetty,A.K., Squirrel,M., Bostock,J., and Rinaldi,A. (2012). Elimination 
of phrenic nerve stimulation occuring during C RT - Follow -up in patients implanted 
with a novel quadripolar pacing lead. J Interv Card Electrophysiol 33, 43 -49. 
Minden,H.H. (2011). Technische Innovationen und Limitationen im Bereich der 
Elektrotherapie. Herzschr. Elektrophys 1, 11 -15. 
Moubarak,G., Bou zeman A., Ollitrault,J., Anselme,F., and Cazeau,S. (2014). 
Phrenic nerve stimulation in cardiac resynchronisation therapy. J Interv Card 41, 
15-21. 
Nof,E., Gurevitz,O., Carraso,S., Bar -Lev,D., Luria,D., Bachar,S., Eldar,M., and 
Glikson,M. (2008). Compariso n of results with different left ventricular pacing leads. 
Europace 10, 35 -39. 
Packer M. (2001). Proposal for a new clinical end point to evaluate the efficacy of 
drugs and devices in the treatment of chronic heart failure. J Card Fail 7, 176 –182. 
Pappone C, Calovic Z, Vicedomini G, Cuko A, McSpadden LC, Ryu K, Jordan CD, 
Romano E, Baldi M, Saviano M, Pappone A, Vitale R, Catalano C, Ciaccio C, 
Giannelli L, Ionescu B, Petretta A, Fragakis N, Fundaliotis A, Tavazzi L, Santinelli 
V. (2015). Improving cardiac resynchronization therapy response with multipoint 
left ventricular pacing: Twelve -month follow -up study. Heart Rhythm 12, 1250 -
1258.  
Rinaldi CA, Burri H, Thibault B, Curnis A, Rao A, Gras D, Sperzel J, Singh JP, Biffi 
M, Bordachar P, Leclercq C. (2015). A  review of multisite pacing to achieve cardiac 
resynchronization therapy. Europace 17, 7 -17. 
Romeyer -Bouchard,C., Da Costa A., Dauphinot,V., Messier,M., Bisch,L., 
Samuel,B., Lafond,B., Ricci,P., and Isaaz,K. (2010). Prevalence and risk factors 
related to i nfections of cardiac resynchronization therapy devices. Eur. Heart J. 31, 
203-210. 
    QP ExCELs  
Version: September 6 , 2019   Page 59 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Shetty,A.K., Duckett,S.G., Bostock,J., Roy,D., Ginks,M., Hamid,S., Rosenthal,E., 
Razavi,R., and Rinaldi,C.A. (2011). Initial single -center experience of a quadripolar 
pacing  lead for cardiac resynchronization therapy. Pacing Clin. Electrophysiol. 34, 
484-489. 
Thibault B., Dubuc M., Khairy P., Guerra P.G., Macle L., Rivard L., Roy D., Talajic 
M., Karst E., Ryu K., et al. (2013). Acute haemodynamic comparison of multisite 
and b iventricular pacing with quadripolar left ventricular lead. Europace 15, 984 -
991. 
Tomassoni G., Baker J., Corbisiero R., Love C., Martin D., Niazi I., Sheppard R., 
Worley S., Beau S., Greer S. et al. (2013). Postoperative performance of the 
Quartet left ve ntricular heart lead. J Cardiovasc Electrophysiol 24, 449 -456. 
Tomassoni GF, Baker J, Corbisiero R, Love CJ, MD, Martin DT, Sheppard RC, 
Worley SJ, Varma N, Niazi I. (2017). Safety and efficacy of Multipoint Pacing in 
Cardiac Resynchronization Therapy: The  MultiPoint Pacing (MPP) IDE Study. 
JACC Clin Electrophysiol 3, 1510 -1518.  
Varma N., Epstein A.E., Irimpen A., Schweikert R., and Love C. (2010). Efficacy 
and safety of automatic remote monitoring for implantable cardioverter -defibrillator 
follow -up: the L umos -T Safely Reduces Routine Office Device Follow -up (TRUST) 
trial. Circulation 122, 325 -332. 
Zanon F, Marcantoni L, Baracca E, Pastore G, Lanza D, Fraccaro C, Picariello C, 
Conte L, Aggio S, Roncon L, Pacetta D, Badie N, Noventa F, Prinzen F. (2016). 
Optimization of left ventricular pacing site plus multipoint pacing improves 
remodeling and clinical response to cardiac resynchronization therapy at 1 year. 
Heart Rhythm 13, 1644 -1651.  
 
    QP ExCELs  
Version: September 6 , 2019   Page 60 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
12. APPENDIX A: DEFINITION OF TERMS  
Abnormal Defibrillation I mpedance  – Defibrillation impedance is typically 
considered abnormal if a measurement is < 25 Ω or > 150 Ω (based on lead model 
and measurement range of the device). Includes high or low shock impedance 
when attempting to deliver a shock.  
Abnormal Pacing I mpedance  – Pacing impedance is typically considered 
abnormal if a measurement is <200 Ω or >3000 Ω (based on lead model and 
measurement range of the device).  
Cardiac Perforation associated with a lead – Penetration of the lead tip through 
the myocardium (including microp erforation), clinically suspected and confirmed by 
chest x -ray, fluoroscopy, echocardiogram, intracard iac electrogram and/or visually . 
Clinical Lead Failure  – Inability of the lead to correctly sense or pace in the heart, 
not attributable to a mechanical  or electrical  failure  of the lead or pulse generator 
and that remains unresolved despite reprogramming and/or repositioning.  
Coronary Sinus Dissection  – A tear that occurs in the wall of the coronary sinus.  
Electrical Lead Failure  – Confirmed or suspected l ead issue that is due to a n 
electrical failure of the lead, such as electrical noise not attributable to other 
causes, and that leads to loss of pacing and/or sensing . Specific types of confirmed 
or suspected electrical lead failure s, such as high impedanc e values , no capture, 
and loss of sensing , are separate  adverse event categories and should only be 
reported once. Confirmed or suspected electrical lead failures caused by induced 
malfunctions, such as lead damage caused during a procedure, are excluded.  
Elevated Pacing Threshold – Either of the following is considered an elevated 
pacing threshold for the Sentus QP lead : 
• At implant: pacing threshold >  3.0 V at 0.4  ms or 0.5 ms  
• At routine  evaluation: pacing threshold >  2.5 V at 0.4  ms or 0.5 ms  
These thresh olds are less than half of the maximum output in BIOTRONIK CRT 
devices and allow for an adequate safety margin.  
Extracardiac Stimulation – Clinical observation of inadvertent nerve/muscle 
stimulation other than cardiac muscle, such as phrenic nerve stimula tion. 
Failure to Capture or Intermittent C apture – Intermittent or complete failure to 
achieve cardiac stimulation at programmed output delivered outside of the cardiac 
refractory period. This will be considered an AE if invasive intervention  is taken. In 
absence of invasive intervention, this will only be considered an AE if there is 
failure to capture at  the permanently programmed output with a minimum 2:1 safety 
margin . Sudden and significant increase  in the pacing threshold value (elevated 
threshold com pared to previous measured value) at which 2:1 safety margin can 
no longer be achieved.  
    QP ExCELs  
Version: September 6 , 2019   Page 61 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Failure to Sense or U ndersensing  – Intermittent or complete loss of sensing or 
failure to detect intended intrinsic cardiac signals (atrial or ventricular) during non -
refractory periods at programmed sensitivity settings. In absence of additional 
invasive intervention, this will only be considered an AE if the loss of sensing is not 
due to a medical reason and cannot be resolved  with reprogramming.  
Hematoma – A localize d collection of extravasated blood, usually clotted, in an 
organ, space, or tissue.  A hematoma is not considered a protocol defined AE 
unless it is a major hematoma related to the implant procedure. See major 
hematoma.  
High Pacing Threshold – High lead pac ing threshold resulting in invasive 
intervention. In absence of invasive intervention, at follow -up, lead threshold that 
has increased two fold from the chronic threshold value, and is unable to achieve a 
2:1 safety margin.  
Incorrect Lead/Header Connection  – Lead connector pin connected to wrong 
header port, such as swapping leads or reversing connector pins, that is not 
identified and corrected prior to the end of the implant/revision procedure.  
Infection  – An invasion and multiplication of microorganisms in body tissues 
causing local cellular injury and requiring intravenous antibiotics and or system 
removal/extraction . 
Lead Conductor Fracture  – A mechanical break within the lead conductor 
(includes connectors, coils and / or electrodes) observed visually,  electrically, or 
radiographically.  
Lead Dislodgment – Radiographic, electrical or electrocardiographic evidence of 
electrode displacement from the original implant site or electrode displacement that 
adversely affects pacing, and/or lead performance.  
Lead Explant  – Surgical removal of a lead either by simple traction (such as 
occurs during the acute implant stage) or using manipulation and tools (as can be 
required for chronically implanted leads).  
Lead Insulation Breach or Insulation Break – A disruption or break in lead 
insulation observed visually, electrically, or radiographically.  
Loose Set Screw  – Header set screw not properly tightened prior to end of 
implant/revision procedure.  
Major Hematoma  – Hematoma requiring evacuation, drainage, blood transfus ion, 
hospitalization or extension of hospital stay to treat hematoma . 
Mechanical Failure  – Malfunction of the lead through a break in the conductor, 
insulation, or connector pin leading to loss of pacing / sensing observed visually, 
electrically, or radiog raphically. Confirmed or suspected mechanical failures 
induced by intervention, such as lead damage caused during a procedure, are not 
protocol defined adverse events.  
    QP ExCELs  
Version: September 6 , 2019   Page 62 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
New York Heart Association (NYHA) Functional Classification – A recognized 
system of cla ssifying the extent of heart failure.  
NYHA 
Class  Symptoms  
I Subjects with cardiac disease, but without resulting limitation of 
physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea, or anginal pain.  
II Subjects  with cardiac disease resulting in slight limitation of 
physical activity. They are comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, dyspnea, or anginal pain.  
III Subjects with cardiac disease resulting in marked limitation  of 
physical activity. They are comfortable at rest. Less than ordinary 
activity causes fatigue, palpitation, dyspnea, or anginal pain.  
IV Subjects with cardiac disease resulting in inability to carry on any 
physical activity without discomfort. Symptoms of cardiac 
insufficiency or of anginal syndrome may be present even at rest. If 
any physical activity is undertaken, discomfort is increased.  
Non-healing Pocket Dehiscence – Separation of wound edges around the pocket 
of the implanted pulse generator that  have not healed.  
Pneumothorax – Air or fluid in the pleural space  surrounding the lung  leading to 
collapse or partial collapse of the lung  requiring observation or chest tube 
placement  
Premature Battery Depletion – Reaching elective r eplac ement indicator (ERI) 
before the predicted date . 
Pulmonary Embolism  – Blockage of the main artery of the lung or one of its 
branches by a substance that has travelled from elsewhere in the body through the 
bloodstream . 
Pulse Generator Failure – Confirmed or suspected puls e generator issue that is 
due to a mechanical failure or electrical malfunction, such as inability to 
communicate with pulse generator, electrical circuit failure, or inability to deliver 
therapy, that is not attributable to another component of the system  or caused by 
an external source.  
Skin Erosion – Deterioration of tissue over an implanted device or the movement 
of a lead toward or through the skin . 
Tamponade – Compression of the heart caused by blood accumulation in the 
space between the myocardium a nd the pericardium . 
Thrombosis – The development of a blood clot in a vein or artery  that leads to the 
obstruction of blood flow . 
    QP ExCELs  
Version: September 6 , 2019   Page 63 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
Twiddler’s Syndrome – A condition where the pulse generator leads are 
dislodged by the subject  unwittingly rotating  or otherwi se moving  the subcutaneous 
pulse generator . 
Venous Occlusion  – Blockage of a vein causing a reduction of blood supply and 
associated symptoms.  
 
    QP ExCELs  
Version: September 6 , 2019   Page 64 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
13. APPENDIX B: PREVIOUS LY IDENTIFIED ADVERS E 
EVENTS  
Based on literature research, the following adverse e vents may  possibly occur as 
medical complications of a  cardiac rhythm management system implant . The most 
common adverse events related to the implantation procedure are listed in  Table 
9a. Expected adverse events related to the left ventr icular pacing threshold test in 
the novel vectors are listed in Table 9d. All references used for this chapter refer to 
the list at the end of this section.  
Adverse events listed below are considered expected unless not previously  
identified in nature, severity or degree of incidence.  
Table 9a: Expected Perioperative E vents  
Frequency  Percent (%) Risk 
Very frequent  
>1 out of 10 patients  7-1945 LV lead exchange due to unsuccessful positioning  
3-2732 Atelec tasis (when thoracotomy necessary)  
3-2732 Pleural effusion (when thoracotomy necessary)  
3-2732 Pneumonia (when thoracotomy necessary)  
Up to 1732 VT/VF exacerbation8,32 
Frequent  
1 to 10 patients out of 
100 1-732 Infection (general)  
5.255,56 - 632 Lead perforation  
3-432 Pericarditis (when patch lead placement necessary)  
Up to 332 Embolism  
Up to 349 Phrenic nerve stimulation  
0.6 – 2.049 Infection requiring reoperation  
0.07*-332,54 Pericardial tamponade (2 -3% during patch lead 
placement)  
0.9331-10.62,49 Lead dislodgement  
0.1231–3.449 Coronary sinus dissection  
Occasionally  
1 to 10 patients out of 
1.000 0.9331 Hematoma  
0.754 Loosening of set screw  
0.0231 -130 Myocardial infarction  
0.0631-232 Cerebrovascular accident, stroke (1 -2% duri ng 
thoracotomy)  
0.630 Lead dysfunction  
0.530 – 0.757 Mortality  
0.530 Severe pocket hematoma  
0.554 Pericardial tamponade (2 -3% during patch lead 
    QP ExCELs  
Version: September 6 , 2019   Page 65 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
placement)  
0.4231 -130 Pneumothorax  
0.331 – 0.449 Cardiac arrest  
0.230 Arrhythmia  
0.2 – 0.349 Respiratory arrest  
0.249 Tamponade  
0.1 - 0.451 Allergic reaction to ionic contrast material  
0.1450 Air embolism  
0.149 Lead fracture/ insulation failure  
0.159 Ventricular fibrillation  
Rare  
1 to 10 patients out of 
10.000  0.0931 Drug reaction  
0.0831 Hemothorax  
0.0731 Cardiac perforation  
0.0431 Phlebitis, superficial  
0.0331 Conduction block  
0.0331 Infection related to device  
0.0331 Peripheral embolus  
0.0252– 0.0453 Allergic reaction to non -ionic contrast material  
0.0231 Phlebitis, deep  
0.0231 Transient ischemic attack  
Very rare  
<1 patient out of 10.000  <0.0131 Cardiac valve injury  
<0.0131 Peripheral nerve injury  
<0.0131 AV-fistula  
Not known  
Frequency not 
assessable on the  
basis of the available 
data 
 Allergic reaction to dexameth asone acetate, 
bleeding32, brachial plexus injury32, device 
migration30,41, diaphragmatic stimulation32, discomfort, 
erosion, exit block32, failure to insulate set screw32, 
hemoptysis32, injury to vagus nerve32, lead 
malpositioning32, lead micro dislocatio n32, local tissue 
reaction30, muscle stimulation30, nerve stimulation 
(general) 30, myocardial lesion30, pocket seroma32, 
subclavian artery puncture32, higher x -ray load due to 
extended fluoroscopy times34, failing of shock test40, 
injury due to implantati on accessories42,44 
Table 9b: Expected Postoperative Events  
Frequency  Percentage (%)  Risk 
 9.720 -3723 Lead failure20,22,23 
Very frequent  2.97–25.424 Inappropriate shocks7,24,25,54 
    QP ExCELs  
Version: September 6 , 2019   Page 66 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
>1 out of 10 patients  Up to 1329 Device explantation (manufacturers` a dvisory: 4%29, 
electronic failure: 2%29, housing defects: 1%29) 
0.31 – 13.64 Phrenic nerve stimulation  
126,21 Lead dysfunction  
1.219 –10.62 Lead dislodgement  
Frequent  
1 to 10 patients out of 
100 1.72 – 9.52 Formation of clinical significant hematoma s 
7.615 – 9.51 Hematoma1,3,15,16,17 
746 Subclavian vein occlusion ≥ 75%  
0.15 - 71 Infections1,5,14 (CRT -D related: 1.91,4,13 - 1.9%1,4; in-
hospital infections: 0.7%12; infections after 
replacement: 1.9%13) 
0.1 – 4.260 Lead fracture  
1.67 – 3.94 Elevated pacing threshold/ loss of capture/ fa ilure to 
capture  
2.430 Aggregate perforation  
3.430 Pocket erosion  
02 – 1.57 Mortality within 30 days after implant (0.4% related to 
implant procedure7) 
1.530 Premature depletion of battery  
1.47 Diaphragmatic muscular stimulation  
0.32 – 1.35 Lead perforation  
1.31 Pericarditis requiring anti -inflammatory agents  
0.057 –
1,212,57,61 Pneumothorax  
0.91 High LV threshold  
0.75 Oversensing  
0.67 Discomfort  
0.67 Pain at device pocket  
0.61 Pericardial effusion requiring intervention  
0.67 Seroma 
0.67 Shoulder pain  
0.54 Lead conductor fracture  
0.530 M. pectoralis tremor  
0.35 – 0.518 Post-operative perforation  
0.754 Thrombosis of brachial, subclavian or jugular veins  
0.312 Acute renal failure requiring hemodialysis  
0.31 Ipsilateral  venous thrombosis  
    QP ExCELs  
Version: September 6 , 2019   Page 67 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
0.37 System - or lead -related arrhythmia  
0.24 Elevated lead impedance  
0.263 Site pain  
0.254 Thrombosis of deep femoral vein  
Rare  
1 to 10 patients out of 
10.000 0.0935 Fluid accumulation due to heart perforation  
0.17 Cardiac/ ca rdiac vein/ coronary sinus dissection  
0.17 Hypotension  
0.0739 Twiddlers syndrome  
Not known  
Frequency not 
assessable on the  
basis of the available 
data 
 Farfield sensing or crosstalk leading to pacemaker 
malfunction30, Pacemaker Mediated Tachycardia30, 
isolation deficiency30, connector deficiency30, 
undersensing30, chronic nerve damage30, fibrotic 
tissue formation30, keloid formation30, formation of 
cysts30, sensing of myopotentials30, pulse generator 
failures26, device extrusion36, 43, vein occlusion37, 
occlusion of coronary sinus38 
Table 9c: Expected Psychological Events  
Frequency  Percentage (%)  Risk 
Very frequent  
>1 out of 10 patients  259,10 - 509 Anxiety or depression9,10,11,27 
Occasionally  
1 to 10 patients out of 
1,000 Up to 16 Psychological into lerance  
Psychosomatic impairment  
Not known  
Frequency not 
assessable on the  
basis of the available 
data 
 Decreased energy levels28, sleep disturbances28, loss 
of libido28, fatigue28, reduced physical capacity28, 
change in body perception28, decreased ac tivity 
level28, sense of impending danger and uncertainty 
about the future28, sensation of losing control28, 
sensation of isolation28, cognitive impairment28, 
decline in social interaction28, fear of shock delivery28, 
fear of death28, fear of device malfun ction28, alteration 
of social relationships28, obsessive thinking about 
shocks28 
Tale 9d: Expected Events due to Pacing Threshold Test of the LV Lead  
Frequency  Percentage (%)  Risk 
Very frequent  
>1 out of 10 patients  3247- 4148 Phrenic nerve stimulation i n 1 or more pacing vectors  
Not known  
Frequency not 
assessable based on  
the available data   palpitations  
    QP ExCELs  
Version: September 6 , 2019   Page 68 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
References  
1. Romeyer -Bouchard C, Da CA, Dauphinot V et al. Prevalence and risk factors related to 
infections of cardiac resynchronization therapy device s. Eur Heart J 2010; 31(2):203 -210. 
2. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation -related 
complications of implantable cardioverter -defibrillators and cardiac resynchronization therapy 
devices: a systematic review o f randomized clinical trials. J Am Coll Cardiol 2011; 58(10):995 -
1000.  
3. Ahmed I, Gertner E, Nelson WB, House CM, Zhu DW. Chronic kidney disease is an 
independent predictor of pocket hematoma after pacemaker and defibrillator implantation. J 
Interv Card Elec trophysiol 2010; 29(3):203 -207. 
4.  Crossley GH, Exner D, Mead RH et al. Chronic performance of an active fixation coronary 
sinus lead. Heart Rhythm 2010; 7(4):472 -478. 
5. Corbisiero R, Armbruster R. Does size really matter? A comparison of the Riata lead family  
based on size and its relation to performance. Pacing Clin Electrophysiol 2008; 31(6):722 -726. 
6. Trappe HJ, Gummert J. [Current Pacemaker and Defibrillator Therapy] [Article in German]. 
Dtsch Arztebl Int 2011; 108(21):372 -380. 
7. Leon AR, Abraham WT, Curtis AB  et al. Safety of transvenous cardiac resynchronization 
system implantation in patients with chronic heart failure: combined results of over 2,000 
patients from a multicenter study program. J Am Coll Cardiol 2005; 46(12):2348 -2356.  
8. Gold MR, Linde C, Abraha m WT, Gardiwal A, Daubert JC. The impact of cardiac 
resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. 
Heart Rhythm 2011; 8(5):679 -684. 
9. van den Broek KC, Habibovic M, Pedersen SS. Emotional distress in partners of patients with 
an implantable cardioverter defibrillator: a systematic review and recommendations for future 
research. Pacing Clin Electrophysiol 2010; 33(12):1442 -1450.  
10. Brouwers C, van den Broek KC, Denollet J, Pedersen SS. Gender disparities in psychologi cal 
distress and quality of life among patients with an implantable cardioverter defibrillator. Pacing 
Clin Electrophysiol 2011; 34(7):798 -803. 
11. Magyar -Russell G, Thombs BD, Cai JX et al. The prevalence of anxiety and depression in 
adults with implantable c ardioverter defibrillators: a systematic review. J Psychosom Res 
2011; 71(4):223 -231. 
12. Reynolds MR, Cohen DJ, Kugelmass AD et al. The frequency and incremental cost of major 
complications among medicare beneficiaries receiving implantable cardioverter -defib rillators. J 
Am Coll Cardiol 2006; 47(12):2493 -2497.  
13. Prutkin J M, Reynolds M R, Bao H, Curtis J P, et al. Rates of and Factors Associated with 
Infection in 200,909 Medicare Implantable Cardioverter -Defibrillator Implants: Results from the 
NCDR®. Circulatio n 2014. 10.1161/circulationaha.114.009081  
14. Tsai V, Chen H, Hsia H, Zei P, Wang P, Al -Ahmad A. Cardiac device infections complicated 
by erosion. J Interv Card Electrophysiol 2007; 19(2):133 -137. 
15. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematom a complications after device 
implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010; 3(4):312 -318. 
16. Ghanbari H, Feldman D, Schmidt M et al. Cardiac resynchronization therapy device 
implantation in patients with therapeutic international normalize d ratios. Pacing Clin 
Electrophysiol 2010; 33(4):400 -406. 
17. Thal S, Moukabary T, Boyella R et al. The relationship between warfarin, aspirin, and 
clopidogrel continuation in the peri -procedural period and the incidence of hematoma 
formation after device impl antation. Pacing Clin Electrophysiol 2010; 33(4):385 -388. 
18. Turakhia M, Prasad M, Olgin J et al. Rates and severity of perforation from implantable 
cardioverter -defibrillator leads: a 4 -year study. J Interv Card Electrophysiol 2009; 24(1):47 -52. 
19. Cheng A, Wan g Y, Curtis JP, Varosy PD. Acute lead dislodgements and in -hospital mortality 
in patients enrolled in the national cardiovascular data registry implantable cardioverter 
defibrillator registry. J Am Coll Cardiol 2010; 56(20):1651 -1656.  
20. Ricci RP, Pignalberi C, Magris B et al. Can we predict and prevent adverse events related to 
high-voltage implantable cardioverter defibrillator lead failure? J Interv Card Electrophysiol 
2012; 33(1):113 -121. 
    QP ExCELs  
Version: September 6 , 2019   Page 69 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
21. Dorwarth U, Frey B, Dugas M et al. Transvenous defibrillation leads:  high incidence of failure 
during long -term follow -up. J Cardiovasc Electrophysiol 2003; 14(1):38 -43. 
22. Hauser RG, Cannom D, Hayes DL et al. Long -term structural failure of coaxial poyurethane 
implantable cardioverter defibrillator leads. Pacing Clin Electro physiol JID - 7803944 2002; 
25(6):879 -882. 
23. Ellenbogen KA, Wood MA, Shepard RK et al. Detection and management of an implantable 
cardioverter defibrillator lead failure: incidence and clinical implications. J Am Coll Cardiol 
2003; 41(1):73 -80. 
24. Dichtl W, Wol ber T, Paoli U et al. Appropriate therapy but not inappropriate shocks predict 
survival in implantable cardioverter defibrillator patients. Clin Cardiol 2011; 34(7):433 -436. 
25. Kleemann T, Hochadel M, Strauss M, Skarlos A, Seidl K, Zahn R. Comparison Between Atrial 
Fibrillation -Triggered Implantable Cardioverter -Defibrillator (ICD) Shocks and Inappropriate 
Shocks Caused by Lead Failure:: Different Impact on Prognosis in Clinical Practice. J 
Cardiovasc Electrophysiol 2012.  
26. Hauser RG, Hayes DL, Almquist AK, Epst ein AE, Parsonnet V, Tyers GF et al. Unexpected 
ICD pulse generator failure due to electronic circuit damage caused by electrical overstress. 
Pacing Clin Electrophysiol  2001; 24: 1046 -1054.  
27. Suzuki T, Shiga T, Kuwahara K et al. Prevalence and persistence of  depression in patients 
with implantable cardioverter defibrillator: a 2 -year longitudinal study. Pacing Clin 
Electrophysiol 2010; 33(12):1455 -1461.  
28. Palacios -Cena D, Losa -Iglesias ME, Varez -Lopez C et al. Patients, intimate partners and 
family experiences of implantable cardioverter defibrillators: qualitative systematic review. J 
Adv Nurs 2011; 67(12):2537 -2550.  
29. Hauser RG, Hayes DL, Kallinen LM, Cannom DS, Epstein AE, Almquist AK et al. Clinical 
experience with pacemaker pulse generators and transvenous le ads: an 8 -year prospective 
multicenter study. Heart Rhythm  2007; 4: 154 -160. 
30. Bericht 2007 des Deutschen Herz -Schrittmacher -Registers“; http://www.pacemaker -
register.de/pdf/zentralregister_herzschrittmacher_bericht07.pdf  
31. Haines DE et al. Implantable cardiov erter-defibrillator registry risk score models for acute 
procedural complications or death after implantable cardioverter -defibrillator implantation; 
Circulation  2011; 123(19): 2069 -2076  
32. Singer I. Complications of Cardioverter -Defibrillator Surgery. Futur a Publishing Company, Inc., 
1994  
33. Gras D, Böcker D, Lunati M, Wellens HJJ, Calvert M, Freementle N, Gervais R, Kappenberger 
L, Tavazzi L, Erdmann E,  Cleland JGF, Daubert J -C; on behalf of the CARE -HF study steering 
committee and investigators. Implantation of the cardiac resynchronization therapy systems in 
the CARE -HF trial: procedural success rate and safety. Europace  2007; 9:516 -522. 
34. Perisinakis K, Theocharopoulos N, Damilakis J, Manios E, Vardas P, Gourtsoyiannis N. 
Fluoroscopically guided implantation o f modern cardiac resynchronization devices: radiation 
burden to the patient and associated risks. J Am Coll Cardiol  2005, 46: 2335 -2339.  
35. Piekarz J, Lelakowski J, Rydlewska A, Majewski J. Heart perforation in patients with 
permanent cardiac pacing – pilot p ersonal observation. Arch Med Sci  2012; 8: 70 -74. 
36. Moubarak G, Duthoit G, Hidden -Lucet F. Unusual pacemaker location due to pocket infection. 
Arch Cardiol Disease  2009; 102:155 -156 
37. Vyselaar JR, Michael KA, Nolan RL, Baranchuk A. Left subclavian vein occlusi on after 
pacemaker insertion. Cardiovasc J Afr  2008; 19:155.  
38. de Voogt W G, Ruiter JH. Occlusion of the coronary sinus: a complication of resynchronisation 
therapy for severe heart failure. Europace  2006; 8: 456 -458. 
39. Fahraeus T, Höijer CJ. Early pacemaker t widdler syndrome Europace 2003; 5: 279 -281  
40. Aydin A, Hartel F, Schlüter M, Butter C, Köbe J, Seifert M et al. Shock efficacy of 
subcutaneous implantable cardioverter -defibrillator for prevention of sudden cardiac death – 
Initial Multicenter experience. Circ Arrhythm Electrophysiol  2012; 5: 913 -919. 
41. Gale CP, Mulley GP. A migrating pacemaker. Postgrad Med J  2005; 81:198 -199. 
42. Dalby MCD, Schilling RJ. Lesson of the issue: Transection, migration and recovery of a peel -
away introducer sheet during permanent pacem aker implantation. Europace  2002; 4: 159 -
    QP ExCELs  
Version: September 6 , 2019   Page 70 of 70 
CONFIDENTI AL: Do not copy or distribute without Sponsor approval  
1Gur DO, Gur O. Pacemaker extrusion: A rare clinical problem mainly in elderly adults JAGS  
2013; 61 (10):1844 -1845  
43. South H, Bains J, Hirsh J. Unusual complication of pacemaker implantation/revision: 
Secondary endoca rditis due to fracture and embolization of an introducer sheath. Cathet 
Cardiovasc Interv  2012; 79:339 -343 
44. Nof E, Gurevitz O, Carasso S, Bar -Lev D, Luria D, Bachar S, Eldar M, Glikson M. Comparison 
of results with  
different left ventricular pacing leads. Europace  2008; 10:35 -39. 
45. Sticherling C, Chough SP, Baker RL, Wasmer K, Oral H, Tada H, Horwood L, Kim MH,  Pelosi 
F, Michaud GF, Strickberger SA, Morady F, Knight BP. Prevalance of central venous 
occlusion in patients with chronic defibrillator leads. A Hea rt J 2001; 141:813 -816. 
46. Metha PA, Shetty AK, Squirrel M, Bostock J, Rinaldi A. Elimination of phrenic nerve 
stimulation occuring during CRT - Follow -up in patients implanted with a novel quadripolar 
pacing lead. J Interv Card Electrophysiol  2012; 33:43 -49. 
47. Shetty AK, Duckett SG, Bostock J, Roy D, Ginks M, Hamid S, Rosenthal E, Razavi R, Rinaldi 
CA. Initial single -center experience of a quadripolar pacing lead for cardiac resynchronization 
therapy. Pacing  
Clin. Electrophysiol 2011;  34:484 -489. 
48. Jamerson D, McNitt S, Polonsky S, Zareba W, Moss A, Tompkins C. Early Procedure -Related 
Adverse Events by Gender in MADIT -CRT. Journal of Cardiovascular Electrophysiology  2014. 
doi: 10.1111/jce.12438.  
49. Ziao PX, Hu ZY, Zhang H, et al. Massive pulmonary air e mbolism during the implantation of 
pacemaker, case reports and literature analysis. Eur Rev Med Pharmacol Sci  2013; 17:3157 -
63.  
50. Marcos SK, Thomsen HS. Prevention of general reactions to contrast media: A consensus 
report and guidelines. Eur Radiol  2001; 1 1:1720 -8. 
51. Brockow K, Christiansen C, Kanny G, Clément O, Barbaud A, Bircher A, DeWachter P, 
Guéant JL, Rodriguez Guéant RM, Mouton -Faivre C, Ring J, Romano A, Sainte -Laudy J, 
Demoly P, Pichler WJ, ENDA and the EAACI interest group on drug hypersensitivity . 
Management of hypersensitivity reactions to iodinated contrast media. Allergy  2005; 60:150 –
158. 
52. Williams JL, Stevenson TR. Complications of Pacemaker Implantation, Current Issues and 
Recent Advances in Pacemaker Therapy, Dr. Attila Roka (Ed.) 2012, ISBN:  978-953-51-0703 -
3, InTech, DOI: 10.5772/48682.  
53. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of Implantable 
Cardioverter Defibrillator Therapy in 440 Consecutive Patients. PACE 2005; 28:926 -932. 
54. Danik SB, Mansour M, Singh J, Reddy VY , Ellinor PT, Milan D et al. Increased incidence of 
subacute lead perforation noted with one implantable cardioverter -defibrillator. Heart Rhythm  
2007; 4:439 -42  
55. Carlson MD, Freedman RA, Levine PA. Lead perforation: incidence in registries. Pacing Clin 
Electrophysiol  2008; 31:13 -5 
56. Stevenson R, Lugg D, Gray R, Hollis D, Stoner M, Williams JL. Pacemaker Implantation in the 
Extreme Elderly. Journal of Interventional Cardiac Electrophysiology  2012; 33:51 -58. 
57. Nowak B, Misselwitz B. Effects of increasing age onto  procedural parameters in pacemaker 
implantation: results of an obligatory external quality control program. Europace 2008; 11:75 -
79.  
58. Alt E, Volker R, Blomer H. Lead fracture in pacemaker patients. Thoracic Cardiovasc Surg 
1987; 35:101 -104. 
59. Williams JL, L ugg D, Gray R, Hollis D, Stoner M, Stevenson R. Patient Demographics, 
Complications, and Hospital Utilization in 250 Consecutive Device Implants of a New 
Community Hospital Electrophysiology Program. American Heart Hospital  2010; 8:33 -39. 
60. Wilkoff BL. Pacem aker and ICD Malfunction – An incomplete Picture. The Journal of the 
American Medical Association  2006; 295:1944 -1946.  